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Abstract 
   Angiogenesis is crucial for cancer progression and its efficiency may affect 
disease evolution, and therefore clinical outcome. Given that cancer-related 
vessel formation relies on the host angiogenic machinery, individual genetic 
variability affecting physiological angiogenesis may impact on cancer 
prognosis.  
   Function of angiogenesis-regulating genes may be affected from single 
nucleotide polymorphisms (SNPs) through the modulation of gene-expression. 
   Prognostic stratification of differentiated thyroid cancer (DTC) is still 
suboptimal as no effective tools are available for identifying patients with 
persistent/recurrent disease after thyroid ablation.  
   Our objective was to evaluate germline SNPs of VEGF-A, VEGFR-2, and 
PDGFR-α, as prognostic markers of clinical outcome in DTC.  
   Multicenter retrospective study including consecutive DTC patients subjected 
to post-surgical follow-up. Eight angiogenesis-related SNPs were included in 
the analysis: -2578 C>A (rs699947), -460 T>C (rs833061), +405 G>C 
(rs2010963), and +936 C>T (rs3025039) for the VEGF-A gene; +1192 C>T 
(rs2305948) and +1719 T>A (rs1870377) for the VEGFR-2 gene; -1309 G>A 
(rs6554162) and -635 G>T (rs1800810) for the PDGFR-α gene. Genotyping 
was performed by means of TaqMan protocol. Prognostic outcome was 
categorized as persistent structural disease, recurrent structural disease, and no 
evidence of disease at last follow-up. Genotypes were analyzed as three-group 
categorical variable and according to the dominant and recessive model. 
Haplotype analysis was performed by means of the Haploview software. 
Positive (PPV) and negative (NPV) predictive values were calculated for 
identified genetic markers.  
   Overall, 249 patients were included. No statistically significant results for 
any of the included SNPs were found at analysis of the overall population. 
Stratified analysis demonstrated that minor homozygous genotypes of VEGF-A 
-2578 C>A and -460 T>C (AA and CC, respectively) conferred protection 
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against recurrent structural disease in AJCC/UICC stage I-II and ATA low-
intermediate risk patients (p=0.035 with RR 0.17 and p=0.031 with RR 0.16, 
respectively). Haplotype analysis of VEGF-A SNPs identified 3 common 
haplotypes: the -2578C, -460T, +405C (CTC);   the -2578A, -460C, +405G (ACG); the -
2578C, -460T, +405G (CTG). ACG and CTG haplotypes were associated with the 
rate of structural recurrent disease in AJCC/UICC stage I-II (p=0.05 with OR 
0.22 and 0.005 with OR 2.6, respectively) and ATA low-intermediate risk 
patients (p=0.036 with OR 0.51 and 0.039 with OR 1.93, respectively), 
exerting protective and deleterious effect, respectively. Analysis of combined-
SNPs genotype found that the ACG homozygous genotype (ACG+/+) offered a 
protective effect against structural recurrence in both stage I-II (p=0.018, RR 
0.2) and ATA low-intermediate (p=0.035, RR 0.17) risk patients, whereas the 
CTG homozygous genotype (CTG+/+) was significantly associated to higher 
rate of structural recurrence in stage I-II (p=0.018, RR=3.55), and was slightly 
deleterious also in ATA low-intermediate risk (p=0.079, RR=2.59) subjects. 
The ACG+/+ genotype retained its prognostic effect in ATA low-intermediate 
risk patients after adjustment for tumour size and multifocality. Both ACG+/+ 
and CTG+/+ genotypes showed high NPV, but only CTG+/+ revealed 
acceptable PPV for structural recurrent disease (42.8% and 33.3% in stage I-II 
and ATA low-intermediate risk patients, respectively).  
   Analysis of germline VEGF-A SNPs may refine risk stratification of DTC 
with “early” disease by providing stable and easily accessible prognostic 
markers.  
   The validation of these markers may facilitate clinical decision-making, 
which is still challenging regarding several therapeutic aspects.  
   The relevance of VEGF-A genetic variability in this group of DTC may 
provide rationale for considering VEGF-A targeted therapies as a possible tool 
for the treatment of subjects harbouring the disease recurrence risk genotype. 
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1. Background 
1.1 Prediction of clinical outcome in differentiated thyroid cancer 
   Thyroid cancer represents not only the most common endocrine malignancy, 
but its incidence is progressively increasing over time in several Western 
countries, including Italy (Albores-Saavedra et al. 2007; Dal Maso et al. 2011; 
Davies et al. 2014). Differentiated thyroid cancer (DTC), including papillary 
and follicular histotypes, arises from epithelial follicular cells (Schlumberger 
1998). It accounts for the vast majority (90%) of thyroid malignancies 
(Sherman 2003) and can be virtually considered responsible for the entire 
increase of thyroid cancer incidence (Siegel et al. 2014), thus representing a 
relevant problem for public health. Despite the raising morbidity, mortality rate 
of thyroid cancer was stable during last decades (Davies et al. 2014). Indeed, 
prognosis of patients affected with DTC is typically favourable with a 10-years 
disease-related survival of 85% (Eustatia-Rutten et al. 2006). This is due to 
both the intrinsic indolent behaviour of the disease (Schlumberger 1998) and 
the efficacy of initial treatment, consisting in total/near-total thyroidectomy 
and, in selected cases,  radioactive iodine  (RAI), followed by suppression of 
thyroid-stimulating hormone (TSH) (Haugen et al. 2016). The low mortality 
rate of DTC makes difficult to perform prognostic studies having as primary 
endpoint overall survival because of the long follow-up needed to achieve a 
significant group of dead patients. By contrast, the persistence of structural 
disease after initial treatment or the development of recurrences after complete 
remission have been reported in about 25-30% of patients (Castagna et al. 
2011; Pitoia et al. 2013; Tuttle et al. 2010b; Vaisman et al. 2012), and are 
strictly related to disease-specific survival (Brown et al. 2011; Mazzaferri et al. 
1994; Tuttle et al. 2010a). Thus, the rate of persistent/recurrent disease or the 
disease-free status (if performing survival analyses) are considered as more 
feasible outcomes to be analyzed and therefore used as primary endpoints in 
the majority of prognostic studies of DTC. Given that the AJCC/UICC 
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(American Joint Commettee on Cancer/Union for International Cancer 
Control) system was able to predict mortality but not persistence/recurrence 
(Baek et al. 2010; Orlov et al. 2009; Tuttle et al. 2010b; Vaisman et al. 2012), a 
great effort has been done in the last decade to build novel staging systems 
specifically dedicated to the prediction of persistent/recurrent disease. 
Particularly, each of the major societies dealing with thyroid diseases (ATA 
[American Thyroid Association], ETA [European Thyroid Association], and  
LATS [Latin American Thyroid Society]) has validated a categorical 
classification identifying subgroups with different risk of persistent/recurrent 
disease (Pacini et al. 2006; Pitoia et al. 2013; Pitoia et al. 2009). Nevertheless, 
the long-term risk stratification obtained by the mentioned systems is still 
suboptimal as all of them showed a proportion of variance explained, a 
statistical measure of how well a staging system can predict the outcome of 
interest (Schemper et al. 1996), less than 30% (Momesso et al. 2014). In order 
to refine the risk estimate of persistent/recurrent disease, recent guidelines from 
the ATA have introduced a personalized non-categorical model based on the 
concept of “continuum of risk”, where further variables were added in order to 
perfectly fit individual clinico-pathological features and provide a quantitative 
determination of the risk  (Haugen et al. 2016). Thus, the identification and 
characterization of novel prognosticators of persistent/recurrent disease, 
including molecular markers, is crucial for empowering this model.  
 
1.2 Molecular prognostication of differentiated thyroid cancer 
   Although molecular prognostication of DTC, namely the understanding of 
the possible relationship between those genetic alterations with demonstrated 
pathogenetic role and the clinical outcome, has been widely studied in last 
several years, it still represents an evolving field. Indeed, any molecular marker 
has a well-defined role in the risk-stratification of DTC, and the introduction of 
molecular prognosis into “real-life” clinical practice is still far to be performed. 
Historically, RET rearrangements and BRAF mutation, genetic alterations 
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specifically occurring in PTC, have represented the mainstays of molecular 
research about thyroid carcinogenesis, being the most studied and characterized 
molecular abnormalities in this field. Thus, we will firstly focalize current role 
of these molecular markers as prognosticators in DTC.  Afterwards, we will 
discuss about emerging molecular markers, specifically focusing on TP53 and 
TERT promoter mutations and the co-occurrence of driver mutations. Finally, 
we will provide some insights about the possible future role of non-tissutal 
molecular markers. 
 
1.2.1 RET rearrangements 
   RET/PTC are a group of chimeric oncogenes (with RET/PTC 1 and 3 
variants being the most frequent) generated by the fusion of the catalytic 
domain of the tyrosine kinase receptor RET to the 5’ terminal region of 
heterologous genes (Santoro et al. 2006). RET/PTC is an exclusive occurrence 
of the thyroid gland (Nikiforova et al. 2000), and its pathogenetic role in DTC 
has been deeply described (Jhiang et al. 1998; Powell et al. 1998; Santoro et al. 
1993; Tallini et al. 1998). In last years, the introduction of highly sensitive 
techniques allowed the detection of non-clonal mutational events, namely the 
presence of RET rearrangements in a small proportion of tumour cells, or even 
in one single cell. This significantly changed some of pre-existing notions 
about RET/PTC, allowing the detection of the rearrangements also in benign 
thyroid diseases (Marotta et al. 2011a). Particularly, we searched for RET/PTC 
1 and 3 by using a high sensitive method, namely Southern Blot on RT-PCR 
products. We detected the rearrangements in 36% of PTC, a higher percentage 
as compared with what previously found by using less sensitive techniques 
(Jhiang et al. 1998; Santoro et al. 1992), and in a relevant portion (13.3%) of 
thyroid nodules with benign histology (Guerra et al. 2011).  
   The biological significance of non-clonal occurrence of RET/PTC in both 
malignant and benign nodules is still a challenging issue (Marotta et al. 2010a). 
We tried to provide some insights about this aspect by comparing clinical 
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evolution of benign nodules with or without non-clonal RET/PTC occurrence, 
showing that the presence of RET rearrangements, even as non-clonal, was 
associated with more rapid volume increase (Marotta et al. 2010b; Sapio et al. 
2011). This suggests that non-clonal RET/PTC may be considered as a 
biologically relevant event.  
   By the prognostic sight, some evidence suggested that RET/PTC 1 was 
associated with more favourable behaviour of PTC (Nikiforov 2004). 
Furthermore, PTC harbouring RET rearrangements, particularly RET/PTC 1, 
had a very low probability of progression to poorly differentiated and 
anaplastic carcinomas, as compared with those carrying BRAF and RAS 
mutations (Mayr et al. 1997; Soares et al. 1998; Tallini et al. 1998). Despite 
these data, the strict dependence from the sensitivity of the detection method 
and the biological difference between clonal and non-clonal mutation, which 
needs to be further defined, strongly hampered analysis and validation of 
RET/PTC in the prognostic setting. Furthermore,  pre-clinical studies identified 
RET/PTC as a weak tumour-initiating factor and suggested that secondary 
genetic or epigenetic changes were required for full neoplastic transformation 
(Powell et al. 1998; Wang et al. 2003). This makes unlikely the driver role of 
RET rearrangements in tumour progression and therefore its impact on 
prognosis. Owing this set of data, RET/PTC has no current role in the 
prognostic stratification of PTC.  
 
1.2.2 BRAFV600E 
   The T1799A transverse point mutation of the proto-oncogene BRAF, 
resulting in the valine-to-glutamate (V600E) amino-acidic substitution, is 
nearly the only BRAF mutation found in thyroid cancer, with a very few 
exceptions for the K601E and A598V missense mutations, the AKAP9/BRAF 
recombination, the 1799-1801 deletion and the 1799-1816 insertion (Ciampi et 
al. 2005; Hou et al. 2007b; Santarpia et al. 2009; Xing et al. 2005). BRAFV600E 
represents the most common genetic alterations in PTC (approximately 45% of 
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cases) (Marotta et al. 2011b; Xing 2005), and its pathogenetic role has been 
widely proved by pre-clinical studies (Knauf et al. 2005; Liu et al. 2007).    
   Unlikely RET rearrangements, several authors reported a clear association of 
BRAFV600E with molecular features suggestive of biological and clinical 
aggressiveness. Particularly, the mutation was associated with decreased or 
absent expression of thyroid iodide-handling genes (the sodium-iodide 
symporter, the TSH receptor, the pendrin gene [SLC26A4], the 
tireoperossidase, and the thyroglobulin) (Durante et al. 2007; Xing 2007), 
whom expression was demonstrated to be strictly dependent from that of  
BRAFV600E (Chakravarty et al. 2011; Liu et al. 2010). Furthermore, BRAF 
mutation was associated with overexpression of many tumour-promoting 
factors, such as VEGF-A and c-MET (Xing, 2007). By the clinico-pathological 
sight, BRAFV600E was associated with the tall cell variant of PTC, which 
represents the most aggressive histological subtype (Ghossein et al. 2007; 
Milione et al. 2010). Despite still controversial, the majority of studies also 
reported the association of mutated BRAF with several other clinico-
pathological features having a negative prognostic impact, such as lymph node 
metastases, extra-thyroidal extension and advanced disease stage (Frasca et al. 
2008; Kebebew et al. 2007; Lee et al. 2007a; Wang et al. 2008; Xing et al. 
2005).  
   Owing this body of evidence, BRAFV600E has been considered the best 
candidate as molecular prognosticator of PTC and several prognostic studies 
have been dedicated to assess its relationship with clinical outcome. After a 
wide series of single-center studies showing controversial results, 2 large 
multicenter cohorts have been recently analyzed for assessing the impact of 
BRAF mutation on mortality and recurrence, respectively. The first paper 
including 1849 patients showed the association of mutated BRAF with 
increased disease specific mortality at univariate analysis (Xing et al. 2013a). 
More importantly, the second one including 2099 patients demonstrated an 
independent association between BRAF mutation and recurrent disease both in 
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the overall PTC population and after stratification for histotypes (classic and 
follicular variant) (Xing et al. 2015).  
   Despite the unequivocal association with disease recurrence, clinical 
application of BRAFV600E as prognostic marker is hampered by its low 
specificity. Indeed, analysis from the largest meta-analysis available to date 
(2167 patients) showed acceptable sensitivity (65%), but poor specificity for 
the prediction of recurrent disease with a positive predictive value (PPV) of 
only 25% (Tufano et al. 2012). Thus, current role of mutated BRAF for the risk 
stratification of PTC is limited, as it is unlikely to be used in isolation, but only 
in a multivariable context, combined with other prognostic features. To date,  
the 2015 ATA guidelines do not suggest the routinary determination of BRAF 
status, but consider BRAFV600E as an information to be included (if present) for 
the risk estimate of recurrent disease in ATA low-risk patients according to the 
“continuum of risk” model (Haugen et al. 2016).  
   Our recent study about the clonality of BRAF mutation in PTC (Guerra et al. 
2012b) has opened a burning issue among researchers dealing with thyroid 
carcinogenesis because of its possible impact on both the biological role and 
the clinical implications of BRAFV600E. We searched for BRAF mutation in 
PTC surgical samples by means of pyrosequencing,  a sequencing-by-synthesis 
method that measures the incorporation of each of the four nucleotides at each 
template position in an automated process involving a pyrosequencer device 
(Ronaghi et al. 1998). As demonstrated by many studies from our and other 
research groups (Guerra et al. 2014; Jo et al. 2006), pyrosequencing showed 
higher sensitivity in detecting mutated BRAF as compared with dideoxy 
sequencing. More importantly, pyrosequencing allowed the careful 
quantification of the percentage of mutated alleles and therefore of the portion 
of tumour cells harbouring BRAFV600E. Among 41 BRAF-mutated PTC, only 4 
cases (about 10%) were consistent with a clonal mutation showing a 
percentage of mutated alleles of nearly 50%. By contrast, in the majority of  
PTC (27, about 65%) BRAFV600E alleles were in the range of 25 to 5.1%, 
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which was consistent with a subclonal mutational event. Our results were 
exactly replicated by a subsequent study from another Italian research group 
(Gandolfi et al. 2013). In order to support these findings and to assess the 
clinical implications of performing a quantitative analysis of BRAF mutation, 
we planned a prognostic study with inclusion of 168 patients, demonstrating 
that the percentage of mutated alleles significantly impacted on the risk of 
recurrence (Guerra et al. 2012a). Particularly, BRAF-mutated tumours with 
more than 30% mutated alleles showed lower disease-free survival, as 
compared with those harbouring less than 30%. The clonality of BRAF 
mutation in PTC is still an hot point of current research on thyroid cancer. 
Recently, de Biase and colleagues (de Biase et al. 2014a) have assessed the 
percentage of BRAF-mutated alleles in a PTC series by means of modern and 
more accurate techniques, such as the allele-specific locked nucleic acid PCR 
and 454 next-generation sequencing (de Biase et al. 2014b; Morandi et al. 
2012). They confirmed the heterogeneity of the mutation, demonstrating that 
BRAFV600E was a clonal event in less than 50% of cases. By contrast, the 
recently published study about genomic sequencing of PTC from The Cancer 
Genome Atlas (Agrawal et al. 2014), performed by means of the most 
innovative next-generation sequencing techniques, applied a dedicate software 
(ABSOLUTE package (Carter et al. 2012)) to calculate cancer cell fraction of 
the previously identified driver mutations with inclusion of  BRAFV600E, 
finding that the majority of tumour cells harboured the mutation. Thus, authors 
concluded that mutations of founder genes were always clonal events. Despite 
this result, we consider the issue about the clonality of BRAFV600E still opened. 
The same study from the Cancer Genome Atlas found a wide variation in the 
pattern of gene expression within the cohort of BRAF-mutated tumours, 
meaning that PTCs with BRAF mutation include a spectrum of tumours having 
different biology and clinics. It is our hypothesis that this could be explained 
by the heterogeneity of the mutation.  
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   Although further studies are mandatory for a better definition of this issue, 
quantitative determination of BRAFV600E and therefore categorization of 
mutated tumours basing on the percentage of mutated alleles (or cells bearing 
the mutation) may dramatically change not only the knowledge of the 
biological role of the oncogene, but also its clinico-pathological implications 
including the application as molecular prognosticator. Indeed, larger prognostic 
studies may allow to test and identify a cut-off of percentage of BRAF-mutated 
alleles, with the aim of  improving specificity and therefore PPV for disease 
recurrence, which represents the main limit of qualitative BRAFV600E 
determination in the prognostic setting.  
 
1.2.3 Emerging molecular markers: TP53, TERT promoter, and co-
occurring driver mutations 
   Despite limited in its clinical application, BRAFV600E is the more powerful 
molecular prognosticator of DTC. Unfortunately, other genetic abnormalities 
historically associated to DTC (including RAS point mutations and 
PAX8/PPARγ rearrangement, which are mostly detected in FTC (Xing 2013)) 
have failed to demonstrate enough prognostic impact and are not currently 
considered as feasible prognosticators (Nikiforova et al. 2009; Xing et al. 
2013b). In recent years, mutations of other 2 genes, the tumour suppressor 
TP53 and the promoter of the catalytic subunit of the telomerase TERT, are 
gaining growing relevance in this field.  
   Although typically considered as a marker of tumour dedifferenziation and 
detected in a wide portion of poorly differentiated and anaplastic thyroid 
cancer (Donghi et al. 1993; Fagin et al. 1993), recent mutational analysis by 
means of next-generation sequencing techniques has identified TP53 mutations 
also in a low percentage of DTC, namely 3.5% of PTC and  11% of oncocytic 
FTC (Nikiforova et al. 2013). Despite the limited samples size, authors 
reported a more aggressive clinical behaviour for this little subgroup of TP53-
mutated tumours.  
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   In last years, mutations of the TERT promoter have represented the focus of 
a relevant part of translational cancer research (Huang et al. 2013). Recently, 
the mutations 1295228 C>T, termed C228T, and 1295250 C>T, termed 
C250T, leading to an increase of translational activity and therefore to 
telomerase activation and immortalization of cancer cells,  were detected in 
follicular cell-derived thyroid cancers. As for TP53, TERT-promoter mutations 
were more frequent in less differentiated tumours, but involved also a 
significant portion of DTC (7-22% of PTC and 14-17% of FTC) (Landa et al. 
2013; Melo et al. 2014). Importantly, the mutations revealed strong prognostic 
impact, being identified as independent risk factor for persistent disease, distant 
metastases, and disease-specific mortality (Melo et al. 2014).  
   Basing on the reported data, both TP53 and TERT promoter mutations are 
promising tools in the field of molecular prognostication of DTC. Although 
further studies are needed mainly to confirm the negative prognostic impact of 
TP53, it seems that these markers may identify a small subgroup of tumours 
having a highly aggressive behaviour. Thus, mutations of TP53 and TERT 
promoter may have higher specificity and PPV for persistence/recurrence, as 
compared with  BRAFV600E. Furthermore, both the markers seems to be 
associated with BRAF-mutation (Landa et al. 2013; Liu et al. 2013; Melo et al. 
2014), thus suggesting a possible synergistic interplay. Thus, co-occurrence of 
TP53 and TERT promoter may in part explain the wide biological and clinical 
variance characterizing BRAF-mutated PTC (Agrawal et al. 2014), and may 
therefore be used for identifying those BRAF-mutated tumour with worst 
outcome (Xing et al. 2014). To conclude, larger and dedicated studies are 
needed to assess the actual accuracy of TP53 and TERT promoter mutations as 
predictors of clinical outcome among DTC-patients, thus allowing their 
introduction into clinical practice.  
   The co-existence of driver mutations within the same tumour was previously 
considered as typical of less differentiated and more biologically aggressive 
forms of follicular-derived thyroid cancer, namely poorly and anaplastic 
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histotypes (Garcia-Rostan et al. 2005; Hou et al. 2007a; Liu et al. 2008). 
Recently, the next generation sequencing analysis performed by Nikiforova et 
al. (Nikiforova et al. 2013) have represented a breakthrough, reporting the co-
occurrence of drivers mutations also in a small portion, namely 4%, of DTC 
(Nikiforova et al. 2013). Even more importantly, this mutational status was 
associated to an  aggressive clinical evolution and the presence of distant 
metastases. This led the latest ATA guidelines (Haugen et al. 2016) to consider 
the combination of mutations involving multiple founder genes as an 
independent genetic signature of aggressiveness, which allows the 
identification of a small subgroup of tumours with extremely aggressive 
behaviour. Within this model, BRAFV600E is considered as the main “actor” 
whereas TERT promoter and TP53, but also PIK3CA, AKT1, or RET/PTC 
mutations are considered as co-occurring events. The proposal of this multi-
genetic approach of risk estimate has the aim to overcome the limit that any 
genetic alteration known to be associated with DTC has, taken alone, enough 
specificity for identifying persisting/recurring patients. Nevertheless, this 
model is still at a preliminary level and further studies are needed to validate it.  
 
1.2.4 Non-tissutal prognosticators  
   To date, molecular analysis of DTC, and therefore molecular prognostication, 
is based exclusively on tissue markers. This represents a limit as tumour tissue, 
including surgical samples but also fine-needle ago-biopsy specimens, is not 
always available. Furthermore, a different mutational status may occur in 
metastatic sites as compared with primary tumour, thus hampering tissue-based 
molecular characterization. Therefore, the identification of non-tissutal markers 
may facilitate and empower molecular prognostication of DTC.  
   Given that BRAFV600E is the more frequent somatic mutation and the main 
prognosticator of DTC, several authors searched for the mutation in circulating 
free DNA (Marotta et al. 2011b). Firstly, Chuang et al. analyzed serum of a 
small series of patients, demonstrating that 60% of cases who were positive for 
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BRAFV600E in primary tumours also had detectable circulating BRAF mutation 
(Chuang et al. 2010). Afterwards, Cradic et al. investigated whether BRAF 
mutation could be detected in the blood of patients with residual or metastatic 
disease, finding the mutation in 21% of cases (Cradic et al. 2009). By contrast, 
recent data failed to detect circulating BRAFV600E in 94 serum samples from 
patients with PTC harbouring the mutation at the somatic level by using a 
quantitative PCR method (Kwak et al. 2013). This discrepancy could be related 
to the use of assay reagents with inadequate sensitivity and/or not optimized for 
plasma samples in addition to uncontrolled pre-analytical steps. Recently, 
research by Pupilli et al. further empowered the use of circulating BRAF 
mutation as biomarkers in DTC (Pupilli et al. 2013). Authors demonstrated that 
the percentage of BRAFV600E detected in the serum increased progressively 
across cytological categories, being higher in patients with histologically 
confirmed thyroid cancer compared to those with benign histology. 
Furthermore, analysis of the mutation before and after treatment clearly 
indicates an association between the mutation and the presence of active 
disease. Thus, BRAF mutation detected on circulating DNA represents a 
promising tool to be specifically analyzed also for the prognostic setting. 
   Molecular prognostication of DTC may be further improved by the 
application of microRNAs (miRNAs), which are short (about 19–22 
nucleotides), non-coding RNA sequences having relevant role in cancer 
development and progression through their regulatory activity on gene 
expression at both the transcriptional and post-transcriptional level (Calin et al. 
2002; Ma et al. 2007). To date, several miRNAs have been found to be 
deregulated in PTC (He et al. 2005; Nikiforova et al. 2008; Pallante et al. 2006; 
Tetzlaff et al. 2007). Particularly, miR-146b, miR-221, and miR-222, have 
been identified as the most deregulated, showing increases of 11- to 19-fold. 
Therefore, many authors have focused the association of miRNAs, particularly 
those previously mentioned, with the clinical outcome. Firstly, Gao et al. 
analyzed miRNAs expression in three subpopulations of PTC cell lines with 
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increased lymph node metastatic potency compared with the control 
subpopulations (Gao et al. 2010). MiR-146b, miR-221, and miR-222 were 
confirmed to be overexpressed in PTC tissue, compared with normal thyroid 
tissue, and also were associated with high-risk features such as extra-thyroidal 
extension, lymph node metastasis, distant metastasis, recurrence, and 
BRAFV600E mutation. Afterwards, studies from Chou et al. showed that BRAF-
mutated PTC had higher miR-146b expression as compared with those not 
carrying the oncogene (Chou et al. 2010). Furthermore, they performed a 
follow-up study  demonstrating poorer overall survival among patients with 
high levels of miR-146b (Chou et al. 2013). Two research groups found an 
association between miR-146b and miR-222 overexpression and distant 
metastasis, recurrence and BRAF expression (Lee et al. 2013; Yip et al. 2011). 
Indeed, Zhou et al. found that overexpression of miR-221 was associated with 
extra-thyroidal extension, lymph node metastasis, advanced disease stages, and 
BRAF mutation (Zhou et al. 2012). In all mentioned studies, prognostic impact 
of miRNAs was based on the evaluation of the expression on tumour tissue. 
Nevertheless, tumour-derived miRNAs are also released into the bloodstream 
(Mitchell et al. 2008), where they can be detected and therefore used as 
circulating biomarkers. Although reliability and accuracy of circulating 
miRNAs as tumour markers is limited by the possible discordant distribution 
between tissue and the bloodstream (Garcia et al. 2008; Heegaard et al. 2012), 
they are considered promising diagnostic and prognostic tools in various types 
of cancers, such as lung, stomach, and ovary neoplasms (Cheng et al. 2011; 
Kroh et al. 2010; Shen et al. 2011; Tsujiura et al. 2010). Role of circulating 
miRNAs as biomarkers of thyroid cancer is still under evaluation. Besides 
performing miRNAs evaluation on tumour tissues, the previously mentioned 
study by Lee et al. demonstrated that PTC-related miRNAs can be measured in 
plasma (Lee et al. 2013). Importantly, authors reported that miR-222 and miR-
146b were overexpressed in plasma from patients with PTC compared with 
plasma from healthy individuals and that circulating levels significantly 
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decreased after surgery. This suggests a close relationship between circulating 
miRNAs  and active disease. To date, studies specifically assessing feasibility 
of circulating miRNAs in the prognostic setting are missing, so their 
introduction into clinical practice is still far from reality.   
 
1.3 Angiogenesis and cancer 
   Angiogenesis is a physiological process consisting in growth and 
development of new blood vessels from pre-existing vasculature (Norrby 
2006). It is involved in several aspects of human physiology, such as 
embryogenesis, tissue growth and development, inflammation, wound healing 
and placental development (Carmeliet 2003).  
   Nevertheless, angiogenesis plays a role also in many pathological processes, 
including cancer (Folkman 1995). Indeed, an adequate supply of oxygen, 
metabolites and an effective way to remove waste products are required for 
neoplastic tissues, similarly to normal ones (Papetti et al. 2002). These 
requirements depend not only from the tumour type, but widely vary basing on 
the course of tumour progression (Hlatky et al. 2002). Particularly, formation 
of new vasculature is considered crucial for tumour maintenance and 
progression hesitating to metastatic disease, rather than initial neoplastic 
transformation (Hanahan et al. 2000). This is confirmed by the observation that 
vascularity is associated with aggressive behaviour and poor prognosis in 
different types of cancer (Jubb et al. 2004), thus leading recent anti-cancer 
research to focus on the development and subsequent introduction into clinical 
practice of a set of anti-angiogenic molecules, which are typically indicated in 
those patients with advanced disease stage and/or experiencing escape from 
conventional therapies (Bridges et al. 2011; Welti et al. 2013). Importantly, 
anti-angiogenic treatment is gaining relevant role in advanced forms of 
endocrine tumours, including DTC, which are poorly responsive to 
conventional anti-cancer treatments, such as cytotoxic agents and radiotherapy 
(Marotta et al. 2013). 
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1.3.1 Molecular mechanisms of angiogenesis in cancer 
   Angiogenesis is a complex process regulated by multiple agents, being the 
VEGF-A and its downstream system the main one, and by the interaction of 
several cellular types, being the endothelial-cell the main one (Carmeliet et al. 
2011). Indeed, activation of new blood vessels development results from the 
balance of a wide range of molecules, which are strictly interactive and may act 
as angiogenic “activators” or “inhibitors” (Carmeliet 2000). These factors 
typically act by binding tyrosine-kinase receptors, thus activating their 
downstream molecular cascades (Carmeliet et al. 2011). Activators of 
endothelial-cell proliferation and migration, termed angiogenic factors, include 
mainly soluble proteins such as vascular endothelial growth factors (VEGFs), 
fibroblast growth factors (FGFs), platelet-derived growth factor (PDGF), 
placental-growth factor (PlGF), and epidermal growth factor (EGF) (Ferrara et 
al. 1989; Folkman 1995), but also molecules of different nature, such as 
lysophosphatic acid (Hu et al. 2001). Among angiogenic  inhibitors,  the first 
factor to be identified was thrombospondin-1 (Volpert et al. 1995). Afterwards, 
a class of proteins named ‘statins’, derived from larger molecules not  affecting 
angiogenesis, (including angiostatin (O'Reilly 1997), endostatin (O'Reilly et al. 
1997), tumstatin (Maeshima et al. 2001),  and canstatin (Kamphaus et al. 
2000)) has been identified.  
   During adult life, balance between positive and negative regulators of 
angiogenesis is settled to induce a quiescence state, which is typical of adult 
vasculature, with the exception of female reproductive organs, physiologically 
growing organs and injured tissues (Carmeliet 2000). By contrast, the 
occurrence of neoplastic transformation induces an alteration of this balance, 
which is usually defined “angiogenic switch”, thus leading to abnormal 
angiogenesis activation (Dvorak 1986). Tumour angiogenesis mainly mimics 
mechanisms of the physiological counterpart. Indeed, tumours use this host-
mediated process for allowing its maintenance and progression. The primum 
movens is represented by the release of angiogenic factors, which stimulate 
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tyrosine-kinase receptors on endothelial cells of pre-existing blood vessels. 
Despite the complexity of the process, VEGF-A is clearly the leading molecule 
(Fassnacht et al. 2009; Nagy et al. 2007). Indeed, high levels of VEGFA 
expression alone are capable of initiating angiogenesis in a quiescent 
vasculature (Pettersson et al. 2000). Importantly, angiogenic factors are 
released both from tumour cells and from host cells, including endothelial- or 
other myeloid- or stromal- cells  (Lee et al. 2007b; Stockmann et al. 2008). The 
earliest stages of angiogenesis are characterized by vasodilatation and 
increased vascular permeability, which induce extra-vasation of plasma 
proteins and constitution of a provisional matrix. Simultaneously, endothelial 
cells release proteolytic enzymes that allow the degradation of the basement 
membrane and the migration towards the neo-formed matrix (Folkman 1995). 
This is accompanied by the loosening of perycite covering, which is mainly 
related to angiopoietin 2 and its tyrosine-kinase receptor TIE-2 (Holash et al. 
1999). While migrating, endothelial cells also proliferate, with the development 
of a migration column leaded by the so-called tip cells. Therefore, endothelial 
cells gradually adhere each other, forming a lumen. This lumen eventually 
thickens, and, finally, additional pericytes are recruited to form a basal lamina 
surrounding the endothelial cells and completing the development of a new 
blood vessel (Bergers et al. 2003a). In normal angiogenesis, pericyte 
associations reduce endothelial-cell proliferation by decreasing their 
dependence from VEGF-A (Benjamin et al. 1998; Hirschi et al. 1996), thus 
providing a stop signal to angiogenesis. By contrast, the association of 
perycites to vessels is abnormal in tumours, and this may in part explain the 
fact that neoplastic vasculature will never achieve a quiescence phase and will 
be constantly growing (Benjamin et al. 1999; Benjamin et al. 1998). This 
confers to tumour vessels distinctive features, as compared with the normal 
counterpart, including morphological characteristics (irregular shape, 
dilatation, tortuosity and the frequent presence of dead ends) and organization 
(chaotic without clear distinction between arterioles, venules, and capillaries) 
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(Benjamin et al. 1999; Morikawa et al. 2002). These structural abnormalities 
also generate functional impairments, with occurrence of haemorrhage and/or 
thrombosis within the tumour mass.  
   While angiogenesis is the most investigated, other mechanisms of tumour 
vascularisation have been observed in cancer. Firstly, endothelial progenitor 
cells, which can either reside in the vascular wall or migrate from bone marrow 
in response to chemo-attractants released by tumour cells, can differentiate into 
endothelial cells and contribute to vessel formation (Rafii et al. 2002). 
Although several angiogenic factors, including VEGF-A and PlGF, have been 
shown to stimulate this process (Hattori et al. 2002), the entity of endothelial-
precursor-cell incorporation seems to be limited and also dependent from the 
nature of the tumour. However, in some model systems, tumours are mostly 
reliant on this mechanism (Lyden et al. 2001). Other mechanisms of neoplastic 
vascularization include: vascular mimicry, a process where cancer cells replace 
endothelial cells by lining the neo-vessels; vessel cooption, whereby tumour 
cells arise near to (or migrates toward) a pre-existing blood vessel; the 
occurrence of chromosomal abnormalities in putative cancer stems cells 
allowing them to differentiate into endothelial cells. To date, clinical relevance 
of these mechanisms remains unclear (Kirschmann et al. 2012; Ricci-Vitiani et 
al. 2010; Wang et al. 2010), but this redundancy in tumour vessels formation 
has to be kept in mind when planning VEGF-A specific anti-angiogenic 
therapies.  
 
1.3.2 The VEGF-system and its role in physiological and tumour 
angiogenesis  
   The VEGF family is composed by few members with non redundant 
biological activity, including VEGF-A, B, C, D, E, and PlGF (Ferrara et al. 
2003; Neufeld et al. 1999). Among them, VEGF-A is the main actor and, more 
importantly, has a predominant role in the regulation of angiogenesis. It is a 
highly conserved, disulfide-bonded homodimeric glycoprotein of 45 kDa, 
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discovered basing on its ability to increase vascular permeability (Senger et al. 
1983). Analysis of crystal structure revealed that the two chains composing 
VEGF-A are arranged anti-parallel, with receptor binding sites at either end 
(Muller et al. 1997). The human VEGF-A gene is located on the short arm of 
chromosome 6 and consists of eight exons separed by seven introns (Houck et 
al. 1991; Tischer et al. 1991). A promoter of 2.36 kbp has been described in the 
human gene and harbours several consensus-binding sites for transcriptional 
factors, including AP1, AP2 and Sp1, which are strictly regulated by growth 
factors, cytokines, hormones, tumour suppressor genes and oncogenes (Buteau-
Lozano et al. 2002; Pages et al. 2005). An alternative promoter was located 
within the 5’UTR (1038 bp), 633 nucleotides downstream of the main starting 
site (Akiri et al. 1998), and controls transcriptional start at two alternative 
initiation codons. Another crucial region for the VEGF-A physiology is the 
3’UTR (1881 bp), which is the main mediator of VEGF-A mRNA stability 
through the binding of the ARE-binding proteins  (such as AUF1 and 
tristetraprolin) and many miRNAs (miR-20 a/b, miR-106 a/b, miR-17-5p, miR-
16 and miR-15b) (DeMaria et al. 1996; Lei et al. 2009; Stoecklin et al. 2003). 
In vitro, VEGF-A promotes growth and allows survival of vascular endothelial 
cells derived from arteries, veins and lymphatics (Alon et al. 1995; Benjamin et 
al. 1999; Ferrara et al. 2003; Ferrara et al. 2004; Gerber et al. 1998). 
Furthermore, it also demonstrated to promote monocyte chemotaxis (Clauss et 
al. 1990) and to stimulate haematopoiesis through the induction of colony 
formation by mature subsets of granulocyte-macrophage progenitor cells 
(Broxmeyer et al. 1995). Although VEGF-A mainly acts as paracrine mediator, 
an autocrine action has been described in the survival of both endothelial cells 
and hematopoietic stem cells (Gerber et al. 2002; Lee et al. 2007b). 
Importantly, VEGF-A is subjected to alternative splicing, resulting in the 
generation of different isoforms including polypeptides of 206, 189, 165, 145, 
and 121 amino acids (Kowanetz et al. 2006). Among them, VEGF-A165  
represents the predominant isoform in both normal and pathological 
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angiogenesis and is therefore the most studied molecule (Ferrara et al. 1992). 
An additional variant, termed 165b, firstly detected  in normal kidneys, acts as 
endogenous inhibitor of VEGF-A165 and is therefore anti-angiogenic (Woolard 
et al. 2004). Despite having apparently similar biological activity in vitro, 
VEGF-A splice variants significantly differ in their binding to heparin (VEGF-
A was originally purified on heparin affinity columns (Senger et al. 1983)), and 
therefore to cells and matrices (Grunstein et al. 2000; Maes et al. 2002; Park et 
al. 1993; Yu et al. 2002). This affects bioavailability of the molecules and 
therefore their function in vivo. Indeed, the formation of new blood vessels 
requires both long- and short-range guidance cues for directing endothelial 
cells migration (Eichmann et al. 2005; Ruhrberg 2003). VEGF-A165 binds 
proteoglycans and other negatively charged matrices (Ferrara et al. 1992) and 
is both soluble and matrix bound, thus supplying both types of cues. VEGF-
A189 binds heparin more strongly than VEGF-A165, whereas VEGF-A121 is 
acidic, does not bind heparin, and diffuses freely in tissues. Thus, VEGF-A121 
predominantly mediates the long range-  and VEGFA189 the short range- 
guidance, being deficient in the other part of the process. This explains why 
mice expressing only the VEGF-A164 isoform (consider that murine isoforms 
are one amino acid shorter) develop normally, whereas those expressing  only 
VEGF-A120 or VEGF-A188 develop severe vascular abnormalities (Carmeliet 
2003; Ruhrberg 2003). In addition, VEGF-A in vivo activity is also controlled 
by extra-cellular proteolysis. Particularly, proteases such as plasmin, which 
cleaves the C-terminal portion of bound VEGF-A, are required to generate a 
biologically active peptide (Park et al. 1993; Roth et al. 2006).  
   VEGF-A and the other members of its family act by binding three tyrosine-
kinase receptors: VEGFR-1 (Flt-1), VEGFR-2 (KDR), and VEGFR-3. 
Structurally, they consist of seven immunoglobulin-like domains in the 
extracellular part, a single transmembrane region and a consensus tyrosine 
kinase sequence that is interrupted by a kinase-insert domain (Shibuya et al. 
1990; Terman et al. 1991). The major effect of VEGF-A on angiogenesis is 
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obtained by signalling through VEGFR-2 (Ferrara 2009; Nagy et al. 2007). 
Indeed, VEGF-A mutants selectively binding to VEGFR-2 fully maintain their 
capability to stimulate mitoses of endothelial cells and to enhance vascular 
permeability, whereas mutants specific for VEGFR-1 lose both activities 
(Takahashi et al. 1999). Binding of VEGF-A induces VEGFR-2 dimerization 
and auto-phosphorylation, which is followed by phosphorylation of numerous 
downstream proteins, including protein kinase C, phospholipase C-γ, and 
phosphatidylinositol 3-kinase. Another component of the VEGF-A pathway is 
the serine/threonine protein kinase Akt, which regulates endothelial cell 
survival, migration, and tube formation (Sun et al. 2005). Other molecules 
involved in the VEGF-A downstream system are mammalian target of 
rapamycin (mTOR) and endothelial nitric oxide synthase, whom biological 
effect is to enhance vascular permeability (Fukumura et al. 2001a; Sun et al. 
2005). Recently, a role for G proteins was also reported within the VEGF-A-
induced molecular cascade (Mukhopadhyay et al. 2004). Importantly, recent 
findings indicate that biological activity of VEGFR-2 activation depends on its 
sub-cellular localization. Particularly, the induction of arterial morphogenesis 
requires that VEGFR-2 is located in intracellular compartments (Lanahan et al. 
2010). Despite showing high affinity with VEGF-A, biological activity and 
therefore the role in angiogenesis of VEGFR-1 is limited. Indeed, VEGFR-1 
can be considered as a kinase-impaired receptor, meaning that its activation 
through VEGF-A binding leads to a weak kinase activity, not sufficient to 
obtain significant biological effects (Rahimi 2006). However, recent evidence 
reported a more complex and ambiguous role for this receptor, which can act 
by different mechanisms (ligand trapping, receptor homo- and hetero- 
dimerization) and can both stimulate or inhibit angiogenesis. In contrast to 
VEGFR- 1 and VEGFR-2, VEGFR-3 is not activated by VEGF-A but only by 
VEGF-C and VEGF-D. In adults, it is mainly involved in the regulation of 
lymphangiogenesis, and its expression is predominantly  restricted to lymphatic 
endothelial cells (Alitalo et al. 2005). The system also includes co-receptors, 
32 
 
whom role is to facilitate VEGFRs activation (Ferrara et al. 2004). Among 
them, the most important are neuropilins (NRPs), including NRP-1 and NRP-2, 
which not only enhance the activity of VEGFR-2, but can also stimulate 
angiogenesis in an independent way (Neufeld et al. 1999). Particularly, NRP-1 
has been shown to stimulate the migration, but not the proliferation, of cultured 
endothelial cells (Mukhopadhyay et al. 2004).  
   Physiologically, VEGF-A is expressed at low levels in the majority of normal 
adult tissues, with the exception of renal glomerular podocytes, adrenal cortex, 
breast, lung, and also macrophages and cardiac myocytes, where the expression 
is typically high (Berse et al. 1992; Brown et al. 1995; Maharaj et al. 2006). 
The main inductor of VEGF-A expression is hypoxia, which acts by 
stimulating both gene transcription and mRNA stabilization (Claffey et al. 
1996; Levy et al. 1997). As for other oxygen sensitive proteins, crucial role in 
VEGF-A transcription is played by hypoxia-inducible factor (HIF), a 
heterodimeric protein transcription factor. Normally, one HIF-1 peptide, HIF-
1α, is rapidly degraded under normoxic conditions through the ubiquitin 
pathway. By contrast, hypoxia stabilizes HIF-1α, thus allowing its dimerization 
with HIF-1β.  The complex binds to and activates a hypoxia-responsive 
element in the VEGF-A promoter.  
   Besides being crucial in physiological angiogenesis, role of VEGF-A is 
considered predominant also in tumour angiogenesis. Indeed, VEGF-A mRNA 
up-regulation has been detected in many human tumours by means of in situ 
hybridation (Dvorak et al. 1995; Ferrara et al. 1997). Furthermore, different 
types of anti-VEGF treatments, such as VEGF-A and VEGFR-2 monoclonal 
antibodies, small-molecule inhibitors of VEGFR signaling, and antisense 
oligonucleotides, have showed in vivo inhibition of cell-lines from many 
tumours (Ferrara et al. 1997; Kim et al. 1993). VEGF-A up-regulation in 
cancer may be related to several mechanisms, also depending on the tumour 
type. Hypoxic regulation of VEGF-A has been demonstrated in several 
tumours (Semenza 2002). However, VEGF-A expression is also increased by 
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low pH, another hallmark of tumours, and this happens by a HIF-1 independent 
way (Fukumura et al. 2001b). Given that many other tumours show high 
expression of VEGF-A under normoxic conditions, it is conceivable that other 
mechanisms are involved. One of them is the action of oncogenes and tumor 
suppressor genes (Mukhopadhyay et al. 2004; Rak et al. 2004). Indeed, these 
genes act not only by stimulating tumour growth and survival, but also by 
inducing VEGF-A expression and thereby angiogenesis. Another possible 
mechanism is the production (by tumour or host cells) of growth factors 
(including EGF, TGF-α, TGF-β, FGF, and PDGF) or inflammatory cytokines 
(such as IL-1α and IL-6), which have demonstrated to up-regulate VEGF-A 
expression (Ferrara et al. 1997; Neufeld et al. 1999).  
 
1.3.3 The PDGF-system and its role in physiological and tumour 
angiogenesis  
   Like VEGFs, members of the PDGF family are dimers of disulfide-linked 
polypeptide chains (Heldin et al. 1999). Particularly, PDGFs are composed by 
the combination of  four structurally related single polypeptide units, which 
constitute five homo- or hetero- dimers: PDGF-AA, PDGF-BB, PDGF-AB, 
PDGF-CC, and PDGF-DD (Andrae et al. 2008; Heldin et al. 1999; Hoch et al. 
2003). The A-, B-, C-, and D- chains are encoded from different genes, 
localized on the chromosomes 7p22, 22q13, 4q31, and 11q22, respectively, and 
their expression is independently regulated (Betsholtz et al. 2001; Dijkmans et 
al. 2002; Heldin 1992; LaRochelle et al. 2001; Uutela et al. 2001). Whereas the 
AA, BB, and AB isoforms are already active when secreted, PDGF-CC and 
PDGF-DD need to be activated through the cleavage of the CUB domain, 
performed by plasmin or tissue-plasminogen activator (Bergsten et al. 2001; 
LaRochelle et al. 2001).  
   PDGF isoforms act through activation of two structurally related cell surface 
tyrosine-kinase receptors, namely PDGFR-α and PDGFR-β. Coding genes of 
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PDGFR-α and PDGFR-β are localized on chromosomes 4q12 and 5q33, 
respectively. Both receptors are composed from five extracellular 
immunoglobulin-like domains, a transmembrane domain, a juxtamembrane 
domain, splitted kinase domains, a kinase insert domain, and a cytoplasmic tail. 
Each chain of the PDGF dimer interacts with one receptor subunit, thus 
inducing dimerization. Particularly, PDGFRs may constitute three  different 
dimers, namely αα, αβ, and ββ. This makes possible multiple PDGF–PDGFR 
combinations, which allow the PDGF system to exert several and complex 
biological functions. In vivo studies of associations between PDGFs and these 
dimeric receptors have showed as follows: PDGF-AA exclusively act via the 
αα dimer; PDGF-AB and –CC can activate either the αα and the αβ dimers; 
PDGF-DD activates only the ββ dimer, but the possible stimulation of the αβ  
dimer is under study; PDGF-BB is the only isoform showing activity on all 
three dimers (Bergsten et al. 2001; Claesson-Welsh 1994; Claesson-Welsh et 
al. 1988; Gilbertson et al. 2001; LaRochelle et al. 2001; Li et al. 2000; Matsui 
et al. 1989).  
   Following ligand binding and dimerization, PDGFRs undergo auto-
phosphorylation, thus activating an intra-cellular molecular cascade which 
includes: phospholipase C-γ, the G-protein Ras, the phosphatidylinositol 3-
kinase, the growth-factor receptor-bound protein 2, Syp (tyrosine-specific 
phosphatase), Src homology and collagen protein, Crk (a group of adaptor 
proteins) and Src, a family of non-receptor tyrosine kinases (Claesson-Welsh 
1994). This signaling system culminates in the activation of many factors 
which regulate gene expression, including mitogen activated protein kinase 
family members (ERKs, JNKs), and focal adhesion kinase (FAK, a mediator of 
integrin signaling pathway) among others. This leads to the expression of a 
panel of immediate-early-response genes involved in the regulation of cell 
cycle, cell migration, and transformation.  
   A still discussed point about the physiology of the PDGF system is the 
differential activity of the two PDGFR subunits. Studies on NIH3T3 clones 
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demonstrated that the inhibition of PDGFR-α signaling was associated with the 
enhancement of PDGF-BB(which acts through the activation of all three 
receptor dimers)-mediated phenotypic transformation, suggesting that PDGFR-
α antagonizes PDGFR-β-induced transformation (Yu et al. 2000). Thus, signal 
from PDGFR-α is thought to regulate PDGF-pathway leading to cell 
transformation with both positive and negative activity, while PDGFR-β 
mainly stimulate this process. PDGFR-α-mediated simultaneous activation of 
both positive and negative signaling has also been demonstrated in cell 
migration and chemotaxis (Koyama et al. 1994; Yokote et al. 1996). As 
speculated by the majority of authors, this was likely related to the fact that 
PDGFR-α, but not PDGFR-β, may activate stress activated protein kinase-1/c-
Jun NH2-terminal kinase-1 (SAPK1/JNK-1), which in turn antagonizes PDGF-
mediated positive signals. It is conceivable that PDGFR-α-mediated agonistic 
and antagonistic activities for cell growth and motility represent a fine 
molecular mechanism for the modulation of PDGF signal  basing on genetic 
background of the cells and additional extracellular factors. PDGFs, especially 
AA and BB, stimulate proliferation (by acting on G0/G1 transition (Pledger et 
al. 1981; Stiles et al. 1979)) and/or act as chemotactic agents of mesenchymal 
cells, including fibroblast, vascular smooth muscle cells, glial cells, 
macrophages and chondroncytes (Deuel 1987; Heldin 1992). Importantly, 
PDGFs are able to amplify mitogenic signal by stimulating PDGF itself and 
other growth factors expression (Clemmons et al. 1981; Paulsson et al. 1987). 
They are is also involved in the production of collagen (Canalis 1981; 
Narayanan et al. 1983), fibronectin (Blatti et al. 1988), proteoglycan 
(Schonherr et al. 1991), hyaluronic acid (Heldin 1992), and collagenase (Chua 
et al. 1985). These findings are consistent with a relevant role for PDGF 
system in connective tissue homeostasis. Whereas in vitro studies revealed that 
PDGF induced similar set of molecular events and cellular responses in cells 
expressing PDGFR-α or PDGFR-β (Rosenkranz et al. 1999), there was a 
remarkable difference in the phenotype of knock-out mice where genetic 
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deletion of PDGFR-α or PDGFR-β resulted in early embryonic lethality 
through different mechanisms (Soriano 1994, 1997). Indeed, PDGFR-α was 
mainly involved in formation of central nervous system and organogenesis 
(Lindahl et al. 1997), while PDGFR-β was essential for development of 
supportive cells in the vasculature failure. Particularly, pericyte migration to 
the new blood vessels was impaired in PDGFR-β-deficient mice, thus leading 
to abnormal blood vessel formation and defective cardiovascular system 
development (Leveen et al. 1994; Soriano 1994). This indicates a more active 
role for PDGFR-β signal in angiogenesis, as compared with that from PDGFR-
α. It has been demonstrated that endothelial tip cell, located at the leading front 
of angiogenic vessels, release PDGF-BB to chemoattract pericytes specifically 
harbouring the PDGFR-β receptor (Gaengel et al. 2009; Hellberg et al. 2010). 
Furthermore, PDGF-BB also allows pericyte recruitment to tumour vessels 
indirectly, by stimulating VEGF-A expression in the endothelium (Guo et al. 
2003). This activity is crucial for maturation and stabilization of neo-formed 
vessels, as endothelial cells stop proliferating and achieve a quiescence state 
only when covered by mural cells (Gerhardt et al. 2003; Guarani et al. 2011). 
Thus, an abnormal pericytes covering induces an uncontrolled endothelial cell 
growth (Hellstrom et al. 2001), which is typical of tumour angiogenesis. 
Indeed, the overexpression of PDGF-BB in mice paradoxically inhibits tumour 
growth by promoting pericyte recruitment and inducing endothelial cell growth 
arrest (McCarty et al. 2007). Interestingly, a recent study has shown that 
VEGF-A negatively regulates pericyte function and vessel maturation, and this 
happens through the inhibition of the PDGF system (Greenberg et al. 2008).  
   In tumour angiogenesis, activation of the PDGF system mainly relies on the 
production of PDGF-BB by neoplastic cells. Through this mechanism, tumour 
cells  recruit pericytes not only by the direct action on PDGFR-β expressing 
endothelial cells, but also through the overexpression of stromal-cell-derived 
factor-1α. Furthermore, pericytes can also arise from perivascular PDGFR-β+ 
pericyte progenitors, recruited from the bone marrow (Song et al. 2005). Up-
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regulation of PDGFs and PDGFRs has been detected in various cancers, 
including glioma, Kaposi’s sarcoma, prostate cancer, and pancreatic cancer 
(Heinrich et al. 2003; Hermanson et al. 1992; McCarty et al. 2007; Sitaras et al. 
1988). Particularly, PDGFR-α is mainly expressed in tumour cells, whereas 
PDGFR-β is expressed in stromal and peri-vascular cells (Hellstrom et al. 
1999; Hermanson et al. 1992; Soriano 1994). However, genetic alterations 
specifically involving the PDGF system and inducing its activation  have been 
found in different tumours (Simon et al. 1997; Sirvent et al. 2003). Co-
expression of ligands and receptors in malignant cells suggests the existence of 
an autocrine loop for the PDGF system in the stimulation of tumour cells 
growth and motility (Heldin et al. 1987). Particularly, PDGFs, namely the AA 
and BB isoforms (already active before secretion), may induce cellular 
transformation not only by extra-cellular, but also by an intra-cellular autocrine 
mechanism, which is based on the interaction with PDGFRs in the endoplasmic 
reticulum where they are subjected to phosphorylation (Bejcek et al. 1989; 
Keating et al. 1988). In animal tumour models, autocrine activation of PDGF 
signaling promotes breast cancer metastasis (Jechlinger et al. 2006).  
Furthermore, autocrine and paracrine activation of the PDGF system may 
induce epithelial–mesenchymal transition, a characteristic feature of cancer 
invasion and metastasis, in several cancer types, including breast cancer, 
prostate cancer, and mesothelioma  (Bierie et al. 2006; Jechlinger et al. 2006; 
Kong et al. 2008; Patel et al. 2010). The role of PDGF system in tumour 
progression is further confirmed by the fact that PDGFRs inhibition reduces 
growth by determining pericyte detachment and therefore vessel regression 
(Bergers et al. 2003b). Similarly to VEGF system, this  suggest a more active 
role of PDGFs signaling in promoting tumour  progression, rather than initial 
neoplastic transformation. Indeed, expression of PDGF-BB in PDGFR-
negative tumours leads to hypervascularization and accelerated tumour growth 
rates (Nissen et al. 2007; Xue et al. 2012). In a glioma model, tumour-cell-
derived PDGF-BB stimulates migration of PDGFR-β expressing endothelial 
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cells, accelerating tumour progression  (Guo et al. 2003). PDGF-BB also 
stimulates peri- and intra-tumoral lymphangiogenesis by a direct action on 
lymphatic endothelial cells, thus favouring occurrence of metastases in sentinel 
lymph nodes (Bruyere et al. 2008; Cao et al. 2004). However, the involvement 
of PDGF system in both physiological and pathological angiogenesis is highly 
complex, being characterized by strict interactions with other angiogenic 
factors such VEGF-A, angiopoietins, and FGFs (Nissen et al. 2007). This may 
in part explain the dual role of PDGF system in tumour evolution. In primary 
tumours activation of PDGF system has a protective action, as it allows neo-
vessels stabilization and limits tumour cells intra-vasation, thus antagonizing 
neoplastic spread (Gerhardt et al. 2008). In this early phase of tumour evolution 
PDGF blockage can paradoxically promote malignancy. By contrast, activation 
of PDGFRs sustains tumour progression in a more advanced phase of the 
disease, once micro-metastatic sites have been already developed.  
 
1.4 Genetics of angiogenesis and cancer 
 
   Similarly to the majority of biological processes, angiogenesis presents a 
wide variability between individuals. The major factor affecting this variability 
is genetic background. Indeed, a large cohort study of  478 individuals 
demonstrated that genetics accounts for almost 80% of circulating VEGF-A 
variability, whereas environmental factors determined only 20% (Pantsulaia et 
al. 2004). Furthermore, studies of nuclear families revealed significant 
correlations between circulating VEGF-A in all pairs of relatives, excluding 
spouses (Berrahmoune et al. 2007).  
   Given the complexity of angiogenesis, study of the underlying genetic basis, 
the so-called “angio-genome”, is challenging. According to the current 
evidence, various types of genetic variability may affect angiogenesis, and this 
happens mainly through the modulation of gene expression (Rogers et al. 
2012). Thus, a myriad of genetic and molecular modifications, potentially 
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regulating gene expression, may be involved, including genetic mutations or 
single nucleotide polymorphismsb(SNPs) (McCarthy et al. 2008), 
translocations, copy number variations (Beckmann et al. 2007), epigenetic 
changes (DNA methylation and histone modifications) (Schones et al. 2008), 
and miRNAs (Couzin 2008).  
   Although several models have been developed in animals, no assays are 
available for quantifying angiogenic-response in humans. Thus, knowledge 
about human “angio-genome” mainly relies on candidate gene studies, 
focusing on whether genetic variability of genes already known as associated 
with angiogenesis can affect angiogenesis-dependent diseases. Particularly, 
several studies assessing the relationship of angiogenic SNPs with 
susceptibility and aggressiveness of cancer have been performed, with 
heterogeneous results mainly depending on the tumour type (Rogers et al. 
2012). The main weakness of this approach is that no novel genes can be 
found, so it is possible that genetic features strongly affecting angiogenesis 
have not been identified yet. Currently, these studies are mainly performed by 
testing for single SNPs.  
   SNPs are inherited germline genetic variants that are commonly found in the 
human genome (Frazer et al. 2007). As compared with mutations, SNPs often 
involve the substitution of a single nucleotide base, but are more frequent, with 
a minor allele frequency of 1% or more (Efferth et al. 2005). SNPs can be 
found in any part of the human genome, including regulatory regions of genes 
(promoter or 3´-untranslated regions), within intronic or exonic sequences and 
within inter-genic regions. SNPs within a DNA sequence distinguish into three 
subgroups characterized by their location in potentially coding (cSNP), 
regulatory (rSNPs) or splicing (sSNP) regions of the human genome. The 
majority of SNPs are clinically silent without any functional implication on the 
final gene product. Although belonging to a specific gene, SNPs may also be 
able to regulate other genes, either on the same chromosome or other different 
chromosomes. Due to the variations in genetic recombination of different 
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regions of chromosomes, these single variants can often be inherited together 
as a linkage disequilibrium (LD) block, which is defined ‘haplotype’.  
 
1.4.1 VEGF-A SNPs and cancer 
   The human VEGF-A is a highly polymorphic gene, with hundreds of SNPs 
disseminated through the various regions already registered in the National 
Center for Biotechnology Information Databank  (NCBI) SNP database 
(http://www.ncbi.nlm.nih.gov). The majority of SNPs are functionally neutral, 
and those showing association with diseases are believed to modulate VEGF-A 
function by affecting its expression (Je et al. 2009; Renner et al. 2000). Indeed, 
large-scale studies observed that disease-associated SNPs were frequently 
located in non-coding genomic regions (rSNPs), particularly the promoter, the 
5’UTR, and the 3’UTR, which are significantly involved in transcriptional and 
post-transcriptional gene modulation (Arcondeguy et al. 2013).  
   Out of 24 SNPs indentified within the promoter and 5’UTR regions, about 
one-third showed correlation with severity of diseases (Metzger et al. 2015). 
The main hypothesis is that these SNPs may affect VEGF-A function through 
the elimination or creation of transcription-factors binding sites (TFBS), thus 
being able to induce strong modifications in gene expression (Ponomarenko et 
al. 2002; Stenson et al. 2009; Wray 2007). For example, the promoter SNP -
2578 C>A (rs699947) has been associated to severity of many diseases, both 
benign (such as atherosclerosis and rheumatoid arthritis) and malignant (such 
as breast and lung cancer) (Chen et al. 2012; Howell et al. 2005; Jin et al. 2005; 
Kammerer et al. 2010). The minor homozygous genotype AA is associated 
with decreased serum levels of VEGF-A, thus indicating that the SNP affects 
VEGF-A function by acting on its expression (Shahbazi et al. 2002). 
Importantly, it has been reported that the C-allele of the -2578 C>A offered the 
binding for the dimer HIF1α/β, which represents the main mediator of hypoxia-
inducted VEGF-A production, whereas the A-allele eliminates the site 
(Buroker et al. 2013). Thus, the absence of any binding for HIF1α/β may 
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explain the significant reduction of VEGF-A expression in subjects carrying 
the AA-genotype, and therefore the association with disease. Similarly, the 
5’UTR SNP  +405 G>C (rs2010963) is associated to severity of several 
diseases (Awata et al. 2002; Jin et al. 2005), and its GG-genotype, which 
represents the common homozygous variant, is associated with the highest 
VEGF-A production (Watson et al. 2000). Regarding its impact on TFBS, this 
SNP is located within a potential myeloid zinc finger protein binding site and 
may affect the binding specificity (Watson et al. 2000). Particularly, a 
reduction of the binding specificity has been associated to the minor C-allele, 
which may explain its association with a loss in VEGF-A production (Jin et al. 
2005). Despite their impact on TFBS is still unclear, other SNPs of the 
promoter/5’UTR affecting gene function are: the  -460 T>C (rs833061), 
located in the promoter, where a lowered VEGF-A production for carriers of 
the common T-allele was reported (Hansen et al. 2010b); the -1154 G>A 
(rs1570360), located in the promoter, where a reduced VEGF-A production 
was reported for the common G-allele.  
   Regarding SNPs located in the 3’UTR region, it is conceivable that they can 
affect VEGF-A function by acting at the post-transcriptional level, through the 
modification mRNA stability. Among the  3′UTR SNPs, the only one showing 
an association with diseases and with VEGF-A production is the +936 C>T 
(rs3025039), where the minor allele T was associated with significantly lower 
VEGF-A levels (Krippl et al. 2003; Renner et al. 2000).  
   In recent years, growing interest to the assessment of VEGF-A SNPs as 
feasible markers of prognosis in cancer has been observed, particularly for the 
epidemiologically prevalent tumours. Results from different studies were 
sometimes controversial, basing on the tumour type, the geographic area, and 
also whether germline or somatic SNPs were subjected to analysis. In 
colorectal cancer, the SNP +936 C>T revealed the major prognostic 
significance. Of 3 large studies, 2 showed that patients carrying the T allele had 
improved outcome (Dassoulas et al. 2009; Lurje et al. 2008), whereas 1 
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showed worsened outcome related to T allele (Kim et al. 2008b). Importantly, 
the papers reporting the protective effect of the T allele assessed germline 
SNPs, whereas the one showing worsened prognosis performed the analysis at 
the somatic level. There was more consistency with the +405 G>C, where the 
cited papers from both Dassoulas et al. (Dassoulas et al. 2009) and Kim et al. 
(Kim et al. 2008b)  showed improved outcome in patients carrying the C allele, 
despite analysis was performed at the germline and somatic level, respectively. 
By contrast, other 2 studies found no correlation between this SNP and 
prognosis (Hansen et al. 2011; Lurje et al. 2008). The study by Dassoulas 
(Dassoulas et al. 2009) also found an association between the A allele of -2578 
C>A and improved OS but this finding was not confirmed by three other 
studies (Hansen et al. 2011; Kim et al. 2008b; Vidaurreta et al. 2010). Among 
the 5 most important breast cancer studies, SNPs -7 C>T and +405 G>C were 
found to be slightly associated with OS (Koutras et al. 2015). Of 4 papers about  
genitourinary cancers (Kawai et al. 2007; Kim et al. 2005; Li et al. 2005; 
Mucci et al. 2009), only one reported significant results, namely the association 
between the A allele of -2578 C>A and improved OS in renal cell carcinoma 
(Kawai et al. 2007). Nevertheless, another study in bladder cancer did not 
confirm this association (Stenson et al. 2009). Out of 8 gynaecological cancer 
studies (Amano et al. 2008; Goode et al. 2010; Hefler et al. 2007; Lose et al. 
2010; Polterauer et al. 2007), a considerable relationship between the C allele 
of the SNP +405 G>C and poor prognosis was found in two papers (Amano et 
al. 2008; Lose et al. 2010). Furthermore, the -460 T>C was found to be 
associated with OS in some studies (Goode et al. 2010; Lose et al. 2010). 
Among the 4 lung cancer studies, the C allele of +405 G>C, the C allele of -
460T>C and the G allele of -1154G>A were found to be associated with 
improved OS in separate studies (Guan et al. 2010; Heist et al. 2008). The five 
most commonly evaluated VEGF SNPs (+405 G>C, -460 T>C, -1154 G>A, -
2578 C>A and +936 C>T) were also included in a pooled meta-analysis, and a 
strong correlation between the C allele of the SNP +405 G>C and improved 
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OS was observed (hazard ratio: 0.79; 95% CI: 0.67–0.94; p = 0.007) (Eng et al. 
2012).  
   No studies are available about the association between VEGF-A SNPs and 
clinical outcome of thyroid cancer. Nevertheless, a single study by Hsiao et al., 
making the analysis at the germline level, found that the A allele of -2578 C>A 
was associated with increased risk of developing DTC and to the presence of 
lymph node metastases among men (Hsiao et al. 2007). 
 
1.4.2 VEGFR-2 SNPs and cancer 
   Genetic variability may affect the biological function of VEGFR-2. 
Particularly, several SNPs have been identified in both coding and regulary 
regions of the VEGFR-2 gene, with potential impact on protein function. 
Among others, the rSNP -604 C>T (rs2071559),  and the nonsynonimous 
cSNPs 1192 C>T (rs2305948) and 1719 T>A (rs1870377) have been mostly 
characterized regarding their impact on VEGFR-2 function.  
   The -604 C>T is located in the promoter, and research found that genetic 
variants of this SNP suppress transcriptional activity, thus leading to down-
regulation of expression level of VEGFR-2 (Wang et al. 2007). This is likely 
due to alteration of the binding site for transcriptional factor E2F (Wang et al. 
2007). Furthermore, Galan et al. found that the -604 C>T, particularly the C-
allele, exerts inhibition of VEGF-A signal and was associated with increased 
risk of age-related macular degeneration (Garcia-Closas et al. 2007).  
   SNPs 1192 C>T and 1719 T>A are located in exon 7 and 11, respectively, 
which correspond to the third and fifth NH2-terminal immunoglobulin-like 
domains within the extracellular region (Leppanen et al. 2010). C>T variant of 
rs2305948 leads to change of amino acid at residues 297V>I and similar 
change at residues 472H>Q happened with T>A variant of rs1870377. 
Functional research discovered that the exchange of these residues decreases 
the binding efficiency to VEGF-A (Wang et al. 2007; Zhang et al. 2009).  
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   As compared with VEGF-A SNPs, fewer and non conclusive data are 
available about possible impact of VEGFR-2 SNPs on cancer prognosis. In 
colorectal cancer, the -604 CC genotype was associated with increased 
microvessel density and decreased survival, whereas the 1192 CC genotype 
was associated with decreased microvessel density and increased survival 
(Hansen et al. 2010a). Nevertheless, studies on breast and lung cancer did not 
reveal any significant association. Interesting but not conclusive data about a 
possible correlation of VEGFR-2 SNPs with clinical outcome of glioblastoma 
have been also reported (Sjostrom et al. 2011).  
   No studies are available about the association between VEGFR-2 SNPs and 
thyroid cancer. 
 
1.4.3 PDGFRs SNPs and cancer 
   Although up-regulation of the PDGFs and their receptors has been reported 
for many cancers (as aforementioned), the knowledge about association 
between SNPs relying on these genes and cancer is still at a preliminary level 
(Cao 2013). Nevertheless, some data about association of SNPs of  PDGFR-α 
and PDGFR-β with disease are available. Particularly, all identified SNPs are 
located in the promoter regions, thus indicating a possible impact on gene 
expression. Wu et al. reported that the promoter SNP -635 G>T (rs1800810) of  
PDGFR-α was associated with the severity and allergic status of childhood 
asthma (Wu et al. 2006). Kim et al. reported the association of 3 promoter 
SNPs of PDGFR-β (rs3756314, rs3756312, and rs3756311) with schizophrenia 
(Kim et al. 2008a). Besides these benign conditions, De Bustos et al. revealed 
the association of a specific promoter haplotype of PDGFR-α with the 
occurrence of primitive neuroectodermal tumors and ependymomas (De Bustos 
et al. 2005).  
   Our interest in involving the PDGF system in the present study about 
angiogenic SNPs and thyroid cancer follows the findings recently reported by 
Kim et al. (Kim et al. 2012). Indeed, authors found that two promoter SNPs, 
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namely the aforementioned -635 G>T and the -1309 G>A (rs6554162) of 
PDGFR-α, were associated with PTC susceptibility. Particularly, frequencies 
of the A allele of -1309 G>A and the T allele of -635 G>T, therefore the minor 
variants, were decreased in the PTC group, thus suggesting a protective effect. 
This association was also confirmed through haplotype analysis based on the 
identification of the GG and AT blocks. Importantly, analysis was performed 
only at the somatic level.  
   Recently, polymorphic sites within the PDGFR-α promoter have been deeply 
characterized (Joosten et al. 2001), and was clearly demonstrated that they may 
affect the transcriptional regulation of the gene. Particularly, authors identified 
5 promoter haplotypes, displaying wide difference in their ability to induce 
reporter gene expression in human U2-OS osteosarcoma cells. To date, 
transcription factors involved in this haplotype specific PDGFR-α promoter 
regulation remain unknown.  
 
2. Aims of the study 
   General objectives of the study were: a) to find out novel and easily available 
molecular markers that could improve prognostic stratification, and therefore 
clinical management of patients affected with DTC; b) to speculate about the 
biological role of angiogenesis in a “simple” cancer model such as DTC, where 
treatment strategy is almost similar in all patients, independently from initial 
pathological features.  
   Main aim was to evaluate germline SNPs of VEGF-A, VEGFR-2, and 
PDGFR-α, as prognostic markers of clinical outcome in DTC.  
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3. Materials and Methods 
3.1 Patients and samples 
   We performed a multicenter retrospective study involving 4 neighbour 
centers from Naples: University Federico II; INT Pascale; Second University 
of Naples; Cardarelli hospital. The study was approved by the Ethics 
Committees of each included center and informed content was obtained from 
each patient before the enrolment. Inclusion criteria were: a) histological 
diagnosis of DTC at local pathological review; b) diagnosis and follow-up 
entirely performed at a single institution; c) availability of clinico-pathological 
data d) at least 18 months of follow-up after surgery. Exclusion criterium: 
patients younger than 18 years. Blood samples were obtained from consecutive 
DTC patients afferent to the involved centers from October 2013 to October 
2015. At the time of enrolment, all patients were subjected to 
clinical/biochemical/instrumental follow-up after receiving the conventional 
treatment approach (total thyroidectomy with/without RAI, followed by TSH 
suppression). Clinico-pathological data had been prospectively collected 
according to recommendations in each center. All files were reviewed by a 
single investigator (the candidate Vincenzo Marotta). Data recorded included: 
gender (male/female); age at diagnosis (years); histology (histotype and 
variants); primary tumour size (cm); multifocality (yes/no); extra-thyroidal 
extension (yes/no); concomitant Hashimoto’s thyroiditis (yes/no); lymph node 
status (Nx/N0/N1); distant metastasis (yes/no); AJCC/UICC stage (I/II/III/IVa-
b-c); ATA group risk (low/intermediate/high). Data about clinical outcome 
were obtained by consulting the files and, if necessary, by interviewing the 
attending physician or the patient himself. Follow-up data were last updated in 
December 2015 for all included patients. 
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3.2 Polymorphisms 
   Overall, 8 angiogenesis-related SNPs were included in the analysis: -2578 
C>A (rs699947), -460 T>C (rs833061), +405 G>C (rs2010963), and +936 
C>T (rs3025039) for the VEGF-A gene; +1192 C>T (rs2305948) and +1719 
T>A (rs1870377) for the VEGFR-2 gene; -1309 G>A (rs6554162) and -635 
G>T (rs1800810) for the PDGFR-α gene. The selection of this specific set of 
angiogenic SNPs was performed basing on the following criteria: a) previous 
documentation and characterization; b) preceded publications attesting the 
possible impact on protein function; c) previous data about the impact on 
cancer prognosis; d) previous data about the relationship with DTC. Current 
knowledge about each of these issues has been already discussed in the 
Background section. 
3.3 DNA extraction and genotyping 
   DNA was extracted and purified from peripheral blood according  to the 
manufacturer protocol using a QIAamp tissue kit (Qiagen, Hilden, Germany). 
DNA concentration was determined by means of NanoDrop® (Wilmington, 
DE) ND-1000 Spectrophotometer and samples were diluted to 10 ng/µl. SNP 
genotyping was carried out according to the TaqMan® genotyping protocol 
(Applied biosystems StepOnePlusTM) with 20-ng DNA template. The 
TaqMan SNP genotyping  is an advanced, validated, and widely used 
technology having high throughput and low running costs (Borodina et al. 
2004; Giles et al. 2004; Hampe et al. 2001). It requires forward and reverse 
PCR primers, and two differently labeled TaqMan minor groove binder (MGB) 
probes. Briefly, the bi-allelic SNP is located in the middle third of the probe. 
Each allele-specific MGB probe is labeled with a fluorescent reporter dye 
(either a FAM or a VIC reporter molecule) and is attached with a fluorescence 
quencher. When the MGB probe is intact, the reporter dye is quenched. During 
PCR, the 5’-nuclease activity of Taq DNA polymerase cleaves the reporter dye 
(FAM or VIC) from an MGB probe that is completely hybridized to the DNA 
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strand. Once separated from the quencher, the reporter dye fluoresces. By 
contrast, if a single point mismatch is present between the probe and the target 
DNA strand because of a SNP, the binding of the probe to DNA is destabilized 
during PCR, and this prevents the probe cleavage to happen efficiently, thus 
letting the fluorescent reporter dye remain quenched. Therefore, an increase in 
either FAM or VIC dye fluorescence indicates homozygosity for FAM- or VIC 
specific alleles, whereas an increase in the fluorescence of both dyes indicates 
heterozygosity. By means of this method, genotypes of multiple samples can 
be rapidly generated, thus allowing the simultaneous analysis of a SNP in 
many patients. For each analyzed SNP existing and established TaqMan® 
genotyping assays were used. A positive control, previously verified by 
sequencing, was used for confirming homozygous genotypes. We used a 96-
well plate. For overall quality assurance, 10% of analyzed samples were 
randomly selected and analysis was repeated in triplicates. Genotype 
concordance was ≥99%.  
 
3.4 Clinical management during follow-up 
   Despite being a multicenter study, involved centers were neighbours and 
strictly interacting. Thus, clinical management was homogeneous between 
different institutions. All patients with tumours ≥1cm were treated by means of 
total thyroidectomy, whereas DTC <1cm (microcarcinomas) were subjected to 
near-total thyroidectomy. Lymphadenectomy was performed in case of 
clinically involved lymph nodes with therapeutic intent (central and/or lateral 
dissection) and in patients with T3/T4 primary tumour (lesions >4 cm and/or 
with extra-thyroidal extension) without evident lymph node involvement  with 
prophylactic intent (central compartment). Post-surgery RAI ablation was 
performed in all patients with the exception of unifocal microcarcinomas (pT1a 
according to the AJCC/UICC classification). Preparation and treatment 
procedures were in accordance with dedicated guidelines from the Society for 
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Nuclear Medicine and Molecular Imaging and the European Association of 
Nuclear Medicine (Luster et al. 2008; Silberstein et al. 2012). Particularly, I-
131 was administered by means of thyroid-hormone withdrawal (thus 
achieving TSH level ≥30 mU/ml) 5-12 months after surgery. Administered 
activity ranged from 50 to 163 mCi, basing on disease characteristics and 
patient age. Importantly, all RAI treatments were performed at 2 Nuclear 
Medicine referral centers (University Federico II and INT Pascale), and this 
further ensures homogeneity in treatment procedures. After thyroid ablation, 
patients were subjected to TSH suppressive therapy. During follow-up, patients 
were subjected to clinical (neck palpation), biochemical (thyroglobulin [Tg] Tg 
and Tg-antibodies [AbTg] levels) and instrumental (neck ultrasonography 
[US]) examinations every 6 months. Twelve-eighteen months after surgery 
patients were subjected to recombinant human TSH stimulation test to attest 
remission from disease. During follow-up, patients showing measurable basal 
(under TSH suppression) or stimulated Tg, suspicious neck US findings, or 
both were advised to morphological or functional imaging or both, including 
computed tomography or 18-fluorodeoxyglucose positron emission 
tomography. All ultrasonographically suspicious nodules ≥1 cm in diameter 
underwent fine-needle aspiration with measurement of Tg in the aspirate.  
 
3.5 Definitions of clinical outcome 
   Patients were classified as having no evidence of disease (NED) if at the time 
of final follow-up the suppressed Tg was <1 ng/ml, AbTg were negative, neck 
US did not present suspicious finding, and there were no pathological findings 
on any other study performed for clinically indicated reasons, such as I-131 
whole-body scan, radiography, computed tomography, 18-fluorodeoxyglucose 
positron emission tomography, or biopsy. Patients showing measurable 
basal/stimulated Tg and/or raising AbTg after thyroid ablation until last follow-
up and did not present any structural evidence of disease were classified as 
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having biochemical persistent disease. Patients showing structural evidence of 
disease, independently from Tg and AbTg levels, after thyroid ablation until 
last follow-up were classified as having structural persistent disease. Patients 
achieving remission, defined as a period of NED after conventional therapeutic 
approach, who develop a new biochemical (measurable basal/stimulated Tg 
and/or raising AbTg) or structural evidence of disease were classified as having 
recurrent disease (biochemical or structural). Dates of recurrences were 
carefully recorded in order to calculate the disease-free survival (DFS), defined 
as the length of time after achieving NED in which the patient was without any 
evidence of disease.  
 
3.6 Statistical analysis  
   For all statistical analyses, SPSS version 20.0 for Windows (SPSS Inc., 
Chicago, IL) was used. Chi-square test was applied for assessing Hardy-
Weinberg equilibrium. The deviation of the SNPs Hardy-Weinberg equilibrium 
was established at p>0.05. Relationship of each SNP with clinical outcome and 
with clinico-pathological features at diagnosis was assessed by considering the 
genotype as a three-group categorical variable in accordance to the reference 
model (homozygous common variant versus heterozygous versus homozygous 
minor variant) and by grouping in accordance to the dominant (homozygous 
common variant versus heterozygous + homozygous minor variant) and 
recessive (homozygous common variant + heterozygous versus homozygous 
minor variant) models. In case of minor homozygous genotype frequency 
≤10%, analyses were performed exclusively by means of dominant model. 
Group comparisons of categorical variables were performed by means of chi-
square test. ANOVA T-test was used to compare continuous variables between 
genotypes. Results were reported as number and percentage of genotypes 
within each group for categorical variable and as median[range] for each 
genotype for continuous variable. Relative risk (RR) with 95% confidence 
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interval (CI) was calculated for each variable. Survival analyses were 
performed according to the Kaplan–Meier method, and the log-rank test was 
used to test for differences between groups. Estimate of allelic frequencies and 
haplotype analysis were performed by means of the Haploview software. The 
degree of LD was expressed by Lewontin coefficient (D’) and by coefficient of 
correlation of r2. Both parameters estimate the non-random association of 
alleles at two loci. Association of haplotype frequencies with clinical outcome 
was performed by means of Haploview, and odds ratios (OR) with 95% CI 
were provided by the software. Given that biochemical 
persistences/recurrences hesitate in structural disease only in 20% of cases 
(Haugen et al. 2016),  we decided to exclude these conditions from the 
outcome analysis. Therefore, we considered as prognostic endpoints: persistent 
structural disease, recurrent structural disease, NED at last follow-up, and DFS 
when performing survival analysis. Accuracy of genotypes as prognostic 
markers was assessed according to Galen (Galen 1982), by considering true 
positive (TP), true negative (TN), false positive (FP), and false negative (FN) 
results. The PPV was TP/(TP+FP) and the negative predictive value (NPV) 
was TN/(FN+TN). The 95% CI of all these estimates was also evaluated. 
Binary logistic regression analysis was applied for adjusting genotypes with 
significant association with clinical outcome at univariate analysis for selected 
factors having demonstrated prognostic impact. In multivariate analysis, OR 
with 95% CI were reported. All tests were two sided, and p-values of less than 
0.05 were used for considering an association of statistical significance.  
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4. Results 
4.1 Study cohort 
   Overall, 249 patients were included in the study. Demography, pathological 
features, staging according to the AJCC/UICC system, risk stratification 
according to the ATA guidelines, and clinical outcome are summarized in 
Table 1. Briefly, study population included 46 males (18%) and 203 females 
(82%). Median age at the time of diagnosis was 43 years (range 15-74). Mean 
and median follow-up were 67±54 months and 3.75 years (45 months), 
respectively.   
   As expected, the vast majority of patients (90%) were affected with PTC, 
being the classic variant the most represented subgroup. Forty-one (16%) 
patients were considered as having aggressive histology, with inclusion of 3 
tall cell, 10 diffuse sclerosing, and 4 solid PTC variants, and 24 FTC. 
Remarkable features of our study population were the inclusion of a relevant 
percentage of microcarcinomas (35%) and the low portion of patients showing 
distant metastases at diagnosis (2%). This resulted in lower portion of subjects 
with advanced staging (10% for stage III and 8% for stage IV) and having high 
risk of recurrence (4%), as compared with recent large cohort studies about 
DTC (Castagna et al. 2011; Pitoia et al. 2013; Tuttle et al. 2010b; Vaisman et 
al. 2012).  
   After thyroid ablation, 7 patients (3%) showed persistent structural disease. 
Of them, 4 subjects (57%) had distant metastases at the time of diagnosis. 
Recurrent disease was observed in 42 subjects (17%) achieving a period of 
NED. Importantly, 35 of them (14%) showed structurally confirmed 
recurrence, whereas isolated biochemical recurrence (measurable 
basal/stimulated Tg and/or raising AbTg) without any structural correlate was 
observed in 7 patients (3%). However, at the time of last follow-up 65% of 
patients were classified as NED. 
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Table 1. Demographic, clinico-pathological and prognostic features of the 
study population of patients with DTC ( n=249).  
Median age (years) at diagnosis [range] 43 [15-74] 
Sex-ratio (males/females) 46/203 
Median follow-up (months) after diagnosis [range] 37 [12-281] 
Histology,  number (%) 
Papillary  
    Classic variant 
    Follicular variant 
    Warthin-like variant 
    Hurtle-cells variant 
    Tall-cell variant 
    Diffuse sclerosing variant   
    Solid variant 
    Unknown papillary variant 
Follicular                                            
 
225 (90) 
116 (47) 
50 (20) 
17 (7) 
7 (3) 
3 (1) 
10 (4) 
4 (2) 
18 (7) 
24 (10) 
Median primary tumor size, cm [range] 1.2 [0.1-8.5] 
Microcarcinoma, number (%) 88 (35) 
Multifocality,  number (%) 
Yes 
No 
Unknown 
 
60 (24) 
173 (69) 
16 (6) 
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Extra-thyroidal extension,  number (%) 
Yes 
No 
Unknown 
 
63 (25) 
162 (65) 
24 (10) 
 
Concomitant autoimmune thyroiditis,  number (%) 
Yes 
No 
Unknown 
 
85 (34) 
116 (47) 
48 (19) 
 
Lymph node metastasis,  number (%) 
N0  
N1 
Nx 
 
 
68 (27) 
68 (27) 
113 (45) 
 
Distant metastasis,  number (%) 
Yes 
No  
Unknown 
 
6 (2) 
239 (96) 
4 (2) 
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Radiometabolic treatment,  number (%) 
Yes 
No 
Uncertain 
 
190 (76) 
49 (20) 
10 (4) 
I-131 ablation dose mCi,  median [range] 100 (42-163) 
I-131 cumulative dose mCi,  median [range] 141 (42-964.5) 
AJCC/UICC Stage, number (%) 
 I 
II 
III 
IV 
      IVa 
      IVb 
      IVc 
Uncertain 
 
189 (76) 
 8 (3) 
25 (10) 
20 (8) 
14 (6) 
0 (0) 
6 (2) 
7 (3) 
ATA initial risk classification, number (%) 
Low 
Intermediate 
High 
Uncertain 
 
113 (45) 
118 (47) 
9 (4) 
9 (4) 
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AJCC/UICC:American Joint Commettee on Cancer/Union for International Cancer Control; 
ATA:American Thyroid Association. 
 
4.2 Polymorphisms: alleles and genotypes frequencies and Hardy-
Weinberg equilibrium 
   Genotyping of the 8 selected SNPs was successfully performed in all 
patients. Alleles and genotypes frequencies, as well as results from Hardy-
Weinberg equilibrium test are reported in Table 2 (alleles frequencies reported 
as minor allele frequency [MAF]). Allele frequencies were consistent with 
those reported in the NCBI SNP database for the Caucasian population. 
Furthermore, they were highly similar to those detected  in a cohort of healthy 
control subjects from the same geographic area (n=143, data not shown). 
Genotype frequencies conformed to Hardy-Weinberg equilibrium for all SNPs 
(p>0.05). Five SNPs  (+936 C>T for VEGF-A; +1192 C>T and +1719 T>A for 
VEGFR-2; -1309 G>A and -635 G>T for PDGFR-α) showed minor 
homozygous genotype frequency less than 10% and were therefore analyzed 
basing on the dominant model (as previously specified).  
 
 
Clinical  status at last follow-up ,  number (%) 
Persistent structural disease 
Recurrent disease 
            Biochemical 
            Structural 
NED 
Uncertain 
 
 
7 (3) 
42 (17) 
7 (3) 
35 (14) 
161 (65) 
3 (1) 
57 
 
Table 2. Distribution of genotypes, MAF and results from the Hardy-Weinberg equilibrium test for 
the analyzed SNPs. 
MAF=Minor allele frequency 
 
 
 
 
 
 
 
 
4.3 Association of clinico-pathological factors with clinical outcome  
   In order to attest the consistency of our study population and the accuracy of 
data collection and follow-up assessment, thus facilitating the interpretation of 
translational analysis, we firstly evaluated the relationship between clinico-
pathological factors and clinical outcome.  
   Results from this analysis are reported in Table 3. Our findings were almost 
conformant to what expected basing on the majority of studies about clinical 
prognostication of DTC (Baek et al. 2010; Ghossein et al. 2014; Jukkola et al. 
SNPs Genotype n (%) MAF 
Hardy-Weinberg equilibrium  
p-value 
-2578 C>A (rs699947) CC 92 (37); CA 113 (45); AA 44 (18) 0.404 0.420 
-460 T>C (rs833061) TT 91 (37)  TC 113 (45) CC 45 (18) 0.408 0.394 
+405 G>C (rs2010963) GG 86 (35) GC 123 (49) CC 40 (16) 0.408 0.844 
+936 C>T (rs3025039) CC 190 (76) CT 52 (21) TT 7 (3) 0.133 0.232 
+1192 C>T (rs2305948) CC 193 (78) CT 55 (22) TT 1 (0.5) 0.114 0.273 
+1719 T>A (rs1870377) TT 154 (62) TA 79 (32) AA 16 (6) 0.223 0.24 
-1309 G>A (rs6554162) GG 142 (57) GA 94 (38) AA 13 (5) 0.241 0.774 
-635 G>T (rs1800810) GG 174 (70) GT 70 (28) TT 5 (2) 0.161 0.709 
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2004; Simpson et al. 1987): microcarcinoma (which we used as categorical 
variable to assess the prognostic impact of tumour size) (p<0.0001, RR=0.16, 
95% CI 0.05-0.51), multifocality (p=0.001, RR=3.01, 95% CI 1.53-5.93), 
extra-thyroidal extension (p<0.0001, RR=3.71, 95% CI 1.81-7.61), and lymph 
node metastases (p=0.004, RR=3.5, 95% CI 1.37-8.94) were associated with 
recurrent structural disease among patients achieving NED after thyroid 
ablation; microcarcinoma (p<0.0001, RR=1.48, 95% CI 1.25-1.76), 
multifocality (p<0.0001, RR=0.56, 95% CI 0.41-0.76) extra-thyroidal 
extension (p<0.0001, RR=0.58, 95% CI 0.43-0.76), lymph node metastases 
(p<0.0001, RR=0.51, 95% CI 0.37-0.72), and distant metastasis (p=0.001, RR 
0.21 95% CI 0.03-1-3) were associated with NED at last follow-up;  age at 
diagnosis (≥ 45 years p=0.027, RR=7.4, 95% CI 0.9-60.7), unfavourable 
histology (involving aggressive variants of PTC and FTC) (p=0.005, RR=6.26, 
95% CI 1.45-26.91), multifocality (p=0.006, RR=11.33, 95% CI 1,29-99.4), 
extra-thyroidal extension (p=0.032, RR=5.16, 95% CI 0.97-27.46), and distant 
metastases (p<0.0001, RR=52.54, 95% CI 14.89-184.64)  were associated with 
persistent structural disease.  
   As expected, ATA classification was able to predict all analyzed clinical 
outcomes: recurrent structural disease: p<0.0001; intermediate risk RR=7.72, 
95% CI 2.39-24.91; high risk RR=27.75, 95% CI 7.93-96.99;  NED: p<0.0001; 
intermediate risk RR=0.6, 95% CI 0.5-0.73; high risk RR=0.35, 95% CI 0.26-
0.47; persistent structural disease: intermediate risk RR=1.91, 95% CI 0.17-
20.82; high risk RR=56, 95% CI 7.06-444.05. 
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Table 3. Relationship between clinico-pathological features of DTC at diagnosis and clinical outcome. 
N:number; CI: confidence interval; NED: no evidence of disease; LN: Lymph node; AJCC/UICC: American Joint 
Commettee on Cancer/Union for International Cancer Control; ATA: American Thyroid Association. *Favourable histology 
includes classic, follicular, Warthin-like, and Hurtle-cells variants of papillary thyroid cancer; unfavourable histology 
includes tall-cell, diffuse sclerosing, and solid variants of papillary thyroid cancer and follicular thyroid cancer; 
**Categorization in micro- and macro- carcinoma was used for the analysis. ***Patients not subjected to cervical 
lymphadenectomy (Nx) have been excluded from the analysis. 
 Persistent structural disease, N(%) Recurrent structural disease, N(%) NED, N(%) 
 Yes No 
Relative 
risk(95%CI) p-value Yes No 
Relative risk 
(95%CI) p-value Yes No 
Relative risk 
(95%CI) p-value 
Gender             
      Male 1(2.2) 43(93.5) 0.76(0.09-6.19) 0.801 7(15.2) 36(78.3) 1.14(0.53-2.43) 0.738 31(67.4) 13(28.3) 1.09(0.88-1.36) 0.441 
      Female 6(3) 196(96.6) 1(reference)  28(13.8) 168(82.8) 1(reference)  130(64) 72(35.5) 1(reference)  
Age at diagnosis             
      <45yrs 1(0.7) 135(97.8) 1(reference) 0.027 21(15.2) 114(82.6) 1(reference) 0.65 87(63) 49(35.5) 1(reference) 0.588 
      ≥45 yrs 6(5.4) 104(93.7) 7.4(0.9-60.7)  14(12.6) 90(81.1) 0.86(0.46-1.61)  74(66.7) 36(32.4) 1.05(0.87-1.26)  
Histology*             
      Favourable 3(1.6) 185(97.4) 1(reference) 0.005 22(11.6) 163(85.8) 1(reference) 0.178 127(67.6) 61(32.4) 1 (reference) 0.13 
      Unfavourable 4(9.8) 36(87.8) 6.26(1.45-26.91)  8(19.5) 28(68.3) 1.08(0.57-2.04)  22(55) 18(45) 0.81(0.60-1.09)  
Tumor size**              
   Microcarcinoma 1(1.1) 87(98.9) 0.29(0.03-2.44) 0.229 3(3.4) 84(95.5) 0.16(0.05-0.51) <0.0001 73(83) 15(17) 1.48(1.25-1.76) <0.0001 
   Macrocarcinoma 6(3.7) 152(94.4) 1(reference)  32(19.9) 120(74.5) 1(reference)  88(54.7) 70(43.5) 1(reference)  
Multifocality              
    Yes  4(6.7) 56(93.3) 11.33(1,29-99.4) 0.006 14(23.3) 42(70) 3.01(1.53-5.93) 0.001 26(43.3) 34(56.7) 0.56(0.41-0.76) <0.0001 
    No 1(0.6) 169(97.7) 1(reference)  14(8.1) 155(89.6) 1(reference)  130(75.1) 40(23.1) 1(reference)  
Extra-thyroidal 
extension 
            
    Yes  4(6.3) 58(92.1) 5.16(0.97-27.46) 0.032 15(23.8) 43(68.3) 3.71(1.81-7.61) <0.0001 28(44.4) 34(54) 0.58(0.43-0.76) <0.0001 
    No 2(1.2) 158(97.6) 1(reference)  11(6.8) 147(90.7) 1(reference)  124(76.5) 36(22.1) 1(reference)  
Concomitant 
thyroiditis 
            
     Yes  0(0) 85(73.3) Not assessable 0.132 6(7.1) 79(92.9) 0.49(0.2-1.19) 0.106 64(75.3) 21(24.7) 1.17(0.97-1.41) 0.09 
     No 3(2.6) 111(95.7) 1(reference)  16(13.8) 95(81.9) 1(reference)  73(85.9) 41(35.3) 1(reference)  
LN metastasis***             
      N0 1(1.5) 67(98.5) 1(reference) 0.551 5(7.4) 62(91.2) 1(reference) 0.004 51(75) 17(25) 1(reference) <0.0001 
      N1 2(2.9) 65(95.6) 2.03(0.18-21.85)  17(25) 48(70.6) 3.5(1.37-8.94)  26(38.2) 41(70.6) 0.51(0.37-0.72)  
Distant metastasis             
      Yes 
4(66.7) 2(33.3) 
52.44(14.89-
184.64) 
<0.0001 1(16.7) 1(16.7) 3-64(0.87-15.1) 0.142 0(0) 6(100) 0.21(0.03-1-3) 0.001 
      No 3(1.3) 233(97.5) 1(reference)  32(13.4) 201(84.1) 1(reference)  159(66.5) 77(32.2) 1(reference)  
AJCC/UICC stage             
      I-II 3(1.5) 191(97) 1(reference) 0.008 22(11.2) 169(85.8) 1(reference) 0.075 137(69.5) 57(28.9) 1(reference) 0.002 
      III-IV 4(8.9) 41(91.1) 5.74(1.33-24.78)  9(20) 32(71.1) 1.90(0.94-3.83)  21(46.7) 24(53.3) 0.66(0.47-0.91)  
ATA group              
      Low 1(0.9) 111(98.2) 1(reference) <0.0001 3(2.7) 108(95.6) 1(reference) <0.0001 96(85) 16(14.2) 1(reference) <0.0001 
      Intermediate 2(1.7) 115(97.5) 1.91(0.17-20.82)  24(20.3) 91(77.1) 7.72(2.39-24.91)  61(51.7) 56(47.5) 0.6(0.5-0.73)  
      High 4(44.4) 4(44.4) 56(7.06-444.05)  3(33.3) 1(11.1) 
27.75(7.93-
96.99) 
 0(0) 8(100) 0.35(0.26-0.47)  
60 
 
4.4 Association of genotypes with clinico-pathological features 
This analysis was aimed to identify correlations between SNP genotypes and 
clinico-pathological features, thus providing initial indications about possible 
prognostic impact of included SNPs.  
   Results are reported in Table 4. Schematically, the following associations 
were detected: 
- VEGF-A -2578 C>A (rs699947):  
1. Analysis by means of dominant model revealed an association with 
primary tumour size (p=0.024). Particularly, the minor A allele was 
associated with higher tumour size.  
2. Analysis by means of recessive model revealed a strong association 
with the presence of distant metastases at diagnosis (p=0.002). 
Particularly, the minor homozygous genotype AA was associated to 
the presence of metastases. 
- VEGF-A -460 T>C (rs833061):  
1. Analysis by means of dominant model revealed an association with 
primary tumour size (p=0.023). Particularly, the minor C allele was 
associated with higher tumour size.  
2. Analysis by means of recessive model revealed a strong association 
with the presence of distant metastases at diagnosis (p=0.002). 
Particularly, the minor homozygous genotype CC was associated to 
the presence of metastases.  
Due to the association with distant metastases, minor homozygous genotypes 
of VEGF-A -2578 C>A and VEGF-A -460 T>C (AA and CC, respectively) were 
also associated with the ATA high risk group. 
- VEGF-A +936 C>T (rs3025039):  
1. Analysis, performed exclusively by means of dominant model, 
revealed an association with aggressive histology (p=0.027). 
Particularly, the minor T was the risk allele.  
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2. An association with Hashimoto’s thyroiditis was also detected 
(p=0.039). Particularly, the minor T allele was more frequent 
among patients with concomitant autoimmune thyroiditis. 
- VEGFR-2 +1192 C>T (rs2305948): 
1. Analysis, performed exclusively by means of dominant model, 
revealed an association with gender (p=0.027). Particularly, the 
minor T allele was more frequent in females. 
- PDGFR-α -1309 G>A (rs6554162):  
1. Analysis, performed exclusively by means of dominant model, revealed 
an association with primary tumour size (p=0.02). Particularly, the 
minor A allele was associated to higher volume. 
No significant associations were found for VEGF-A +405 G>C 
(rs2010963), VEGFR-2 +1719 T>A (rs1870377), and PDGFR-α -635 G>T 
(rs1800810). 
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Table 4. 
Relationship 
between 
VEGF-A, 
VEGFR-2, and 
PDGFR-α 
polymorphi ms 
and clinico-
pathological 
features of 
DTC at 
diagnosis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Gender,  
n(%) 
 
Age at diagnosis (yrs), 
median[range] 
Histology,**   
n(%) 
Tumor size (cm),  
median[range] 
Multifocality,   
n(%) 
 Male Female p-value  p-value Favourable Unfavourable p-value  p-value Yes No p-value 
VEGF-A rs699947   0.209  0.067   0.762  0.071   0.699 
CC=92 19(20.7) 73(79.3)  40 [15-65]  17(18.5) 68(73.9)  0.9[0.3-5.5]  24(26.1) 63(68.5)  
CA=113 23(20.4) 90(79.7)  43[17-72]  18(15.9) 88(77.9)  1.3[0.1-8.5]  24(21.2) 80(70.8)  
AA=44 4(9) 40(90.9)  45[22-74]  6(13.7) 34(85)  1.3[0.2-7]  12(27.3) 30(68.2)  
Dominant model (CC vs. CA+AA)   0.498  0.053   0.494  0.024   0.621 
Recessive model (CC+CA vs. AA)   0.077  0.059   0.617  0.235   0.644 
VEGF-A rs833061   0.186  0.097   0.715  0.072   0.857 
TT=91 19(20.9) 72(79.1)  40 [15-65]  17(18.7) 67(73.6)  0.9[0.3-5.5]  23(25.3) 63(69.2)  
TC=113 23(20.4) 90(79.6)  43[17-72]  18(15.9) 88(77.9)  1.3[0.1-8.5]  25(22.1) 79(69.9)  
CC=45 4(8.9) 41(91.1)  45[22-74]  6(13.3) 35(77.8)  1.25[0.2-7]  12(26.7) 31(68.9)  
Dominant model (TT  vs. TC+CC)   0.458 0.086    0.454  0.023   0.791 
Recessive model (TT+TC vs. CC)   0.067 0.067    0.565  0.271   0.720 
VEGF-A rs2010963   0.129  0.745   0.556  0.109   0.867 
GG (n=86) 11(12.8) 75(87.2)  43.5[15-74]  69(80.2) 12(14)  1.4[0.2-7]  23(26.7) 60(69.8)  
GC (n=123) 24(19.5) 99(80.5)  43[17-72]  89(72.4) 23(18.7)  1.2[0.1-8.5]  28(22.8) 84(68.3)  
CC (n=40) 11(27.5) 29(72.5)  40.5[24-62]  32(80) 6(15)  0.8[0.3-5.5]  9(22.5) 29(72.5)  
Dominant model (GG vs. GC+CC)   0.093  0.871   0.391  0.210   0.611 
Recessive model (GG+GC vs. CC)   0.108  0.445   0.729  0.055   0.750 
VEGF-A rs3025039*   0.265  0.429   0.027  0.55   0.499 
CC =190 38(20) 52(27.4)  43[15-74]  37(19.5) 141(74.2)  1.2[0.1-8.5]  48(25.3) 131(68.9)  
CT+TT=59 8(13.6) 51(86.4)  40[21-71]  4(6.8) 49(83.1)  1[0.3-7]  12(20.3) 42(71.2)  
VEGF-R2 rs2305948*   0.027  0.723   0.662  0.656   0.157 
CC =193 30(15.5) 163(84.5)  43[15-74]  33(17.1) 147(76.2)  1.25[0.2-7]  51(26.4) 132(68.4)  
CT+TT=56 16(28.6) 40(71.4)  42[24-62]  8(14.3) 43(76.8)  1[0.1-8.5]  9(16.1) 41(73.2)  
VEGF-R2 rs1870377*   0.853  0.445   0.456  0.197   0.257 
TT=154 29(18.8) 125(81.2)  42.5[15-74]  28(18.2) 118(76.6)  1.1[0.1-8.5]  42(27.3) 107(69.5)  
TA+AA=95 17(17.9) 78(82.1)  43[19-72]  13(13.7) 72(75.8)  1.3[0.2-7]  18(18.9) 66(69.5)  
PDGFR-α  rs6554162*   0.084  0.903   0.930  0.02   0.544 
GG=142 21(14.8) 121(85.2)  42 [19-72]  23(16.2) 108(76.1)  1.1[0.1-6.2]  36(25.4) 96(67.6)  
GA+AA=107 25(23.4) 82(76.6)  43[15-74]  18(16.8) 82(76.6)  1.3[0.2-8.5]  24(22.4) 77(72)  
PDGFR-α  rs1800812*   0.140  0.304   0.829  0.124   0.927 
GG=174 28(16.1) 146(83.9)  42 [15-72]  28(16.1) 133(76.4)  1.2[0.1-8.5]  42(24.1) 120(69)  
GT+TT=75 18(24) 57(76)  43[17-74]  13(17.3) 57(76)  1.2[0.2-7]  18(24) 53(70.7)  
63 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Extra-thyroidal extension,   n(%) 
 
Concomitant thyroiditis,  
n(%) 
LN metastases, 
n(%) 
Distant metastases, 
n(%) 
 Yes No p-value Yes No p-value Nx N0 N1 p-value Yes No p-value 
VEGF-A rs699947   0.687   0.967    0.618   0.004 
CC=92 21(22.8) 64(69.6)  30(32.6) 43(46.7)  39(42.4) 26(28.3) 27(29.3)  2(2.2) 89(96.7)  
CA=113 30(26.5) 69(61.1)  40(35.4) 53(46.9)  52(46) 28(24.8) 33(29.2)  0(0) 110(97.3)  
AA=44 12(27.3) 29(65.9)  15(34.1) 20(45.5)  22(50) 14(31.8) 8(18.2)  4(9.1) 40(90.9)  
Dominant model (CC vs. CA+AA)   0.391   0.796    0.757   0.845 
Recessive model (CC+CA vs. AA)   0.841   0.940    0.320   0.002 
VEGF-A rs833061   0.725   0.901    0.515   0.005 
TT=91 21(23.1) 63(69.2)  29(31.9) 43(47.3)  39(42.9) 26(28.6) 26(28.6)  2(2.2) 88(96.7)  
TC=113 30(26.5) 69(61.1)  40(35.4) 53(46.9)  52(46) 27(23.9) 34(30.1)  0(0) 110(97.3)  
CC=45 12(26.7) 30(66.7)  16(35.6) 20(44.4)  22(48.9) 15(33.3) 8(17.8)  4(8.9) 41(91.1)  
Dominant model (TT  vs. TC+CC)   0.439   0.666    0.832   0.861 
Recessive model (TT+TC vs. CC)   0.927   0.773    0.258   0.002 
VEGF-A rs2010963   0.416   0.286    0.817   0.218 
GG (n=86) 26(30.2) 54(62.8)  28(32.6) 43(50)  41(47.7) 20(23.3) 25(29.1)  4(4.7) 82(95.3)  
GC (n=123) 29(23.6) 78(63.4)  38(30.9) 57(46.3)  56(45.6) 36(29.3) 31(25.2)  2(1.6) 117(95.1)  
CC (n=40) 8(20) 30(75)  19(47.5) 16(40)  16(40) 12(30) 12(30)  0(0) 40(100)  
Dominant model (GG vs. GC+CC)   0.264   0.545    0.579   0.101 
Recessive model (GG+GC vs. CC)   0.295   0.114    0.757   0.273 
VEGF-A rs3025039*   0.798   0.039    0.480   0.683 
CC =190 48(25.3) 126(66.3)  59(31.1) 95(50)  86(45.3) 55(28.9) 49(25.8)  5(2.6) 182(95.8)  
CT+TT=59 15(25.4) 36(61)  26(44.1) 21(35.6)  27(45.8) 13(22) 19(32.2)  1(1.7) 57(96.6)  
VEGF-R2 rs2305948*   0.839   0.789    0.821   0.094 
CC =193 49(25.4) 128(66.3)  68(35.2) 91 (47.2)  88(45.6) 54(28) 51(26.4)  3(1.6) 188(97.4)  
CT+TT=56 14(25) 34(60.7)  17(30.4) 25(44.6)  25(44.6) 14(25) 17(30.4)  3(5.4) 51(91.1)  
VEGF-R2 rs1870377*   0.348   0.436    0.559   0.285 
TT=154 37(24) 106(68.8)  58(37.7) 73(47.4)  66(42.9) 45(29.2) 43(27.9)  5(3.2) 148(96.1)  
TA+AA=95 26(27.4) 56(58.9)  27(28.4) 43(45.3)  47(49.5) 23(24.2) 25(26.3)  1(1.1) 91(95.8)  
PDGFR-α  rs6554162*   0.801   0.494    0.646   0.633 
GG=142  35(24.6) 93(65.5)  51(35.9) 64(45.1)  62(43.7) 42(29.6) 38(26.8)  4(2.8) 136(95.8)  
GA+AA=107 28(26.2) 69(64.5)  34(31.8) 52(48.6)  51(47.7) 26(24.3) 30(28)  2(1.9) 103(96.3)  
PDGFR-α  rs1800812*   0.370   0.988    0.847   0.477 
GG=174 47(27) 111(63.8)  60(34.5) 82(47.1)  77(44.3) 49(28.2) 48(27.6)  5(2.9) 167(96)  
GT+TT=75 16(21.3) 51(68)  25(33.3) 34(45.3)  36(48) 19(25.3) 20(26.7)  1(1.3) 72(75.8)  
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N:number; LN: Lymph node; Nx: patients not subjected to cervical lymphadenectomy; 
AJCC/UICC: American Joint Commettee on Cancer/Union for International Cancer 
Control; ATA: American Thyroid Association. *Polymorphisms analyzed exclusively by 
means of dominant model because of a Minor Homozygous Genotype frequency ≤10%. 
**Favourable histology includes classic, follicular, Warthin-like, and Hurtle-cells variants 
of papillary thyroid cancer; unfavourable histology includes tall-cell, diffuse sclerosing, 
and  solid variants of papillary thyroid cancer and follicular thyroid cancer. 
    
 AJCC/UICC stage, 
 N(%) 
ATA group, 
N(%) 
 
 I-II III-IV p-value Low-intermediate High p-value 
VEGF-A rs699947       
CC=92 76(82.6) 15(16.3) 0.682 88(95.7) 2(2.2) 0.013 
CA=113 87(77) 20(17.7)  104(92) 2(1.8)  
AA=44 34(77.3) 10(22.7)  39(88.6) 5(11.4)  
Dominant model (CC vs. CA+AA)   0.512   0.335 
Recessive model (CC+CA vs. AA)   0.436   0.003 
VEGF-A rs833061   0.736   0.016 
TT=91 75(82.4) 15(16.5)  87(95.6) 2(2.2)  
TC=113 87(77) 20(17.7)  104(92) 2(1.8)  
CC=45 35(77.8) 10(22.2)  40(88.9) 5(11.1)  
Dominant model (TT  vs. TC+CC)   0.553   0.347 
Recessive model (TT+TC vs. CC)   0.488   0.004 
VEGF-A rs2010963   0.265   0.109 
GG (n=86) 67(77.9) 19(22.1)  80(93) 6(7)  
GC (n=123) 94(76.4) 22(17.9)  111(90.2) 3(2.4)  
CC (n=40) 36(90) 4(10)  40(100) 0(0)  
Dominant model (GG vs. GC+CC)   0.299   0.051 
Recessive model (GG+GC vs. CC)   0.126   0.171 
VEGF-A rs3025039*   0.534   0.470 
CC =190 153(80.5) 33(17.4)  178(93.7) 6(3.2)  
CT+TT=59 44(74.6) 12(20.3)  53(89.8) 3(5.1)  
VEGF-R2 rs2305948*   0.060   0.108 
CC =193 157(81.3) 30(15.5)  181(93.8) 5(2.6)  
CT+TT=56 40(71.4) 15(26.8)  50(89.3) 4(7.1)  
VEGF-R2 rs1870377*   0.382    
TT=154 122(79.2) 31(20.1)  145(94.2) 8(5.2) 0.110 
TA+AA=95 75(78.9) 14(14.7)  86(90.5) 1(1.1)  
PDGFR-α  rs6554162*   0.777   0.193 
GG=142 114(80.3) 25(17.6)   129(90.8) 7(4.9)  
GA+AA=107 83(77.6) 20(18.7)  102(95.3) 2(1.9)  
PDGFR-α  rs1800812*   0.888   0.199 
GG=174 138(79.3) 32(18.4)  159(91.4) 8(4.6)  
GT+TT=75 59(78.7) 13(17.3)  72(96) 1(1.3)  
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4.5 Association of genotypes with clinical outcome 
   Results from this analysis are reported in Table 5. No statistically significant 
associations were found between any of the included SNP and clinical outcome 
(p>0.05).  
   Nevertheless, significant trends were observed for the VEGF-A SNPs -2578 
C>A and -460 T>C. Indeed, minor homozygous genotypes of both SNPs (AA 
and CC, respectively) were slightly associated with persistent structural disease 
(p=0.066 and 0.073, respectively) and with recurrent structural disease 
(p=0.066 and 0.059, respectively). Surprisingly, the prognostic impact of the 2 
genotypes was opposite if considering structural persistence or recurrence as 
clinical outcome. Regarding the former, RRs were 3.64 (95% CI 0.84-15.68) 
for the AA genotype of -2578 C>A and 3.54 (95% CI 0.82-15.25) for the CC 
genotype of -460 T>C, meaning that genotypes were associated with higher 
likelihood to have persistent structural disease and had therefore negative 
prognostic impact. By contrast, analysis of recurrent structural disease found 
that RRs were 0.31(95% CI 0.07-1.24) for the AA genotype of -2578 C>A and 
0.30(95% CI 0.07-1.2) for the CC genotype of -460 T>C, indicating that 
genotypes were associated with a reduced risk of developing recurrences after 
a period of NED and were therefore protective.  
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Table 5. Relationship between VEGF-A, VEGFR-2, and PDGFR-α polymorphisms and clinical outcome. 
 
 
N:number; CI: confidence interval; NED: no evidence of disease. ƗSubgroup considered as reference for the assessment of the 
relative risk. *Polymorphisms analyzed exclusively by means of dominant model because of a Minor Homozygous Genotype 
frequency ≤10%.
 Persistent structural disease, N(%) Recurrent structural disease, N(%) NED, N(%) 
 Yes No 
Relative 
risk(95%CI) p-value Yes No 
Relative risk 
(95%CI) p-value Yes No 
Relative risk 
(95%CI) p-value 
VEGF-A rs699947             
CC=92 3(3.3) 89(96.7) 1(reference) 0.110 14(15.2) 75(81.5) 1(reference) 0.178 61(66.3) 31(33.7) 1(reference) 0.971 
CA=113 1(0.9) 111(98.2) 0.27(0.29-2.58)  19(16.8) 92(81.4) 1.08(0.57-2.04)  73(64.6) 39(34.51) 0.98(0.8-1.19)  
AA=44 3(6.8) 39(88.6) 2.19(0.46-10.4)  2(4.5) 37(84.1) 0.32(0.07-1.36)  27(61.4) 15(34.1) 0.97(0.74-1.26)  
Dominant model (CCƗ 
vs. CA+AA) 
  0.79(0.18-3.48) 0.277   0.89(0.47-1.66) 0.715 
  0.97(0.81-1.18) 0.827 
Recessive model 
(CC+CAƗ vs. AA) 
  3.64(0.84-15.68) 0.066   0.31(0.07-1.24) 0.066 
  0.97(0.76-1.25) 0.862 
VEGF-A rs833061             
TT=91 3(3.3) 88(96.7) 1(reference) 0.118 14(15.4) 74(81.3) 1(reference) 0.163 61(67) 30(33) 1(reference) 0.918 
TC=113 1(0.9) 111(98.2) 0.27(0.29-2.56)  19(16.8) 92(81.4) 1.07(0.57-2.02)  72(63.7) 40(35.4) 0.95(0.78-1.17)  
CC=45 3(6.7) 40(88.9) 2.11(0.44-10.05)  2(4.4) 38(84.4) 0.31(0.07-1.31)  28(62.2) 15(33.3) 0.97(0.74-1.26)  
Dominant model (TTƗ  
vs. TC+CC) 
  0.78(0.17-3.42) 0.744   0.87(0.46-1.63) 0.673 
  0.96(0.8-1-15) 0.689 
Recessive model 
(TT+TCƗ vs. CC) 
  3.54(0.82-15.25) 0.073   0.30(0.07-1.2) 0.059 
  0.99(0.78-1.26) 0.96 
VEGF-A rs2010963             
GG (n=86) 4(4.7) 80(93) 1(reference) 0.308 9(10.5) 71(82.6) 1(reference) 0.242 53(61.6) 31(36) 1(reference) 0.106 
GC (n=123) 3(2.4) 119(96.7) 0.51(0.11-2.24)  22(17.9) 97(78.9) 1.64(0.79-3.38)  76(61.8) 46(37.4) 0.98(0.79-1.22)  
CC (n=40) 0(0) 40(100) Not assessable  4(10) 36(90) 0.88(0.29-2.7)  32(80) 8(20) 1.26(1.01-1.58)  
Dominant model (GGƗ 
vs. GC+CC) 
  0.38(0.89-1.69) 0.193   1.45(0.71-2.95) 0.292 
  1.05(0.86-1.28) 0.576 
Recessive model 
(GG+GCƗ vs. CC) 
  Not assessable 0.237   0.64(0.24-1.71) 0.363 
  1.27(1.05-1.54) 0.055 
VEGF-A rs3025039*             
CC =190  5(2.6) 182(95.8) 1(reference) 0.773 26(13.7) 156(82.1) 1(reference) 0.779 127(66.8) 60(31.6) 1(reference) 0.147 
CT+TT=59 2(3.4) 57(96.6) 1.26(0.25-6.36)  9(15.3) 48(81.4) 1.1(0.55-2.21)  34(57.6) 25(42.4) 0.84(0.66-1.07)  
VEGF-R2 rs2305948*             
CC =193 4(2.07) 186(96.4) 1(reference) 0.198 25(13) 161(83.4) 1(reference) 0.324 127(65.8) 63(32.6) 1(reference) 0.397 
CT+TT=56 3(5.4) 53(94.6) 2.54(0.58-11.03)  10(17.9) 43(76.8) 1.4(0.72-2.73)  34(60.7) 22(39.3) 0.9(0.71-1.14)  
VEGF-R2 rs1870377*             
TT=154 4(2.6) 148(96.1) 1(reference) 0.797 20(13) 128(83.1) 1(reference) 0.528 100(64.9) 52(33.8) 1(reference) 0.886 
TA+AA=95 3(3.2) 91(95.8) 1.21(0.27-5.29)  15(15.8) 76(80) 1.22(0.65-2.25)  61(64.2) 33(34.7) 0.98(0.81-1.19)  
PDGFR-α  rs6554162*             
GG=142 5(3.5) 135(95.1) 1(reference) 0.431 17(12) 118(83.1) 1(reference) 0.307 90(63.4) 50(35.2) 1(reference) 0.66 
GA+AA=107 2(1.9) 104(97.2) 0.52(0.1-2.67)  18(16.8) 86(80.4) 1.37(0.74-2.53)  71(66.4) 35(32.7) 1.04(0.86-1.25)  
PDGFR-α  rs1800812*             
GG=174 6(3.4) 166(95.4) 1(reference) 0.355 21(12.1) 145(83.3) 1(reference) 0.189 112(64.4) 60(34.5) 1(reference) 0.868 
GT+TT=75 1(1.3) 73(97.3) 0.38(0.47-1-16)  14(18.7) 59(78.7) 1.51(0.81-2.81)  49(65.3) 25(33.3) 1.01(0.83-1.23)  
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4.6 Association of VEGF-A SNPs with clinical outcome after 
stratification for AJCC/UICC stage and ATA risk group 
   The controversial finding of an opposite prognostic impact of VEGF-A -2578 
C>A and -460 T>C depending on the considered clinical endpoint required a 
more in depth analysis of the actual prognostic value of these SNPs.  
   However, we have previously showed that patients harbouring the AA 
genotype of -2578 C>A and CC genotype of -460 T>C were more commonly 
metastatic at diagnosis, as compared with other genotypes, and that the 
presence of metastases at diagnosis was the most powerful clinical predictor of 
persistent structural disease in our series (see paragraph 4.3). Therefore, 
association with metastases may act as confounding factor generating the 
correlation of the highlighted genotypes with persistent structural disease as 
clinical outcome. Indeed, the majority of patients with the AA and CC 
genotypes (for VEGF-A -2578 C>A and -460 T>C, respectively) having 
persistent structural disease as clinical outcome were metastatic at diagnosis 
(see Figure 1.). By contrast, analysis of recurrent structural disease revealed 
lower rates of recidivisms for the highlighted genotypes, and among these few 
recurring cases about a half showed metastatic disease at diagnosis  (Figure 1.). 
These observations led us to hypothesize that more exhaustive information 
about VEGF-A -2578 C>A and -460 T>C prognostic value could be obtained 
after discriminating between “early” and “advanced” disease. Therefore, we 
decided to re-assess prognostic impact of VEGF-A SNPs by stratifying for two 
major classification system, namely AJCC/UICC (I-II versus III-IV) and ATA 
risk group (low-intermediate versus high risk).  
 
 
 
 
68 
 
 
 
 
 
4.6.1 VEGF-A SNPs and prognosis of early disease: stage I-II and ATA 
low-intermediate risk patients. 
   This analysis was focused on a) stage I-II subjects (according to the 
AJCC/UICC system) including intra-thyroidal tumours equal or less than 4 cm 
in size; b) ATA low-intermediate risk patients (according to the ATA 
guidelines) including a wider range of patients, namely subjects with 
completely resected tumour, without gross extra-thyroidal extension (pT4a-b), 
and without metastatic disease. Given the inclusion of patients with non 
advanced disease with low likelihood to have persistent disease after 
conventional therapeutic, we decided to assess the rate of recurrent structural 
disease as single clinical endpoint.  
   Results are reported in Table 6. Analysis of stage I-II patients included 197 
out of 249 subjects. The AA and CC genotypes of -2578 C>A and -460 T>C 
were both associated with reduced risk of recurrent structural disease (p=0.018 
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and 0.016, respectively), showing RRs of 0.2 (95% CI 0.02-1.42) and 0.19 
(95% CI 0.02-1.38), respectively. Analysis of ATA low-intermediate risk 
subjects involved 231 out of 249 patients. The AA and CC genotypes of -2578 
C>A and -460 T>C were both associated with recurrent structural disease 
(p=0.035 and 0.031, respectively), demonstrating to exert protective action 
with RRs of 0.17 (95% CI 0.02-1.22) and 0.16 (95% CI 0.02-1.18), 
respectively.  
   Prognostic impact of minor homozygous genotypes of  -2578 C>A and -460 
T>C was further demonstrated by means of survival analysis, being DFS the 
endpoint (see Figure 2.).  Indeed both the AA and CC genotype, for the SNPs -
2578 C>A and -460 T>C respectively, were associated with longer DFS, as 
compared with other genotype subgroups (common homozygous and 
heterozygous). This association was confirmed in both stage I-II and ATA low-
intermediate risk patients. Here we report median DFS and p-values from the 
survival analysis analysis.  
1) Stage I-II patients: a) -2578 C>A: median DFS 34 months for the AA 
genotype versus 30.6 months for the CC+CA genotypes; p=0.017; b)-
460 T>C: median DFS 36 months for the CC genotype versus 30.3 
months for the TT+TC genotypes; p=0.014. 
2) ATA low-intermediate risk patients: a) -2578 C>A: median DFS 37 
months for the AA genotype versus 31.4 months for the CC+CA 
genotypes; p=0.03; b)-460 T>C: median DFS 38 months for the CC 
genotype versus 31.4 months for the TT+TC genotypes; p=0.026. 
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Table 6. Relationship between VEGF-A polymorphisms and recurrent disease in AJCC/UICC stage I-II and ATA low-
intermediate risk DTC patients. 
  
N:number; CI:confidence interval; inter AJCC/UICC: American Joint Commettee on Cancer/Union for International 
Cancer Control; ATA: American Thyroid Association. ƗSubgroup considered as reference for the assessment of the relative 
risk. *Polymorphisms analyzed exclusively by means of dominant model because of a Minor Homozygous Genotype 
frequency≤10%. 
 
 
 
 
 
 AJCC/UICC stage I-II, N(%) ATA classification low-intermediate risk, N(%) 
 Recurrence No recurrence 
Relative 
risk(95%CI) p-value Yes No 
Relative risk 
(95%CI) p-value 
VEGF-A rs699947         
CC=92 11(12) 65(70.7) 1(reference) 0.058 14(15.2) 75(81.5) 1(reference) 0.108 
CA=113 15(13.3) 76(67.3) 1.13(0.55-2.33)  17(15) 92(81.4) 0.99(0.51-1.89)  
AA=44 0(0) 31(70.4) 0.2(0.02-1.42)  1(2.3) 36(81.8) 0.17(0.02-1.26)  
Dominant model (CCƗ vs. CA+AA)   0.84(0.41-1.75) 0.659   0.78(0.41-1.49) 0.461 
Recessive model (CC+CAƗ vs. AA)   0.2(0.02-1.42) 0.018   0.17(0.02-1.22) 0.035 
VEGF-A rs833061         
TT=91 11(12.1) 64(70.3) 1(reference) 0.053 14(15.4) 74(81.3) 1(reference) 0.098 
TC=113 15(13.3) 76(67.3) 1.12(0.55-2-29)  17(15) 92(81.4) 0.98(0.51-1.87)  
CC=45 0(0) 32(71.1) 0.19(0.02-1.38)  1(2.2) 37(82.2) 0.16(0.02-1.21)  
Dominant model (TTƗ  vs. TC+CC)   0.83(0.40-1.71) 0.617   0.77(0.4-1.46) 0.637 
Recessive model (TT+TCƗ vs. CC)   0.19(0.02-1.38) 0.016   0.16(0.02-1.18) 0.031 
VEGF-A rs2010963         
GG (n=86) 7(8.1) 56(65.1) 1(reference) 0.417 7(8.1) 70(81.4) 1(reference) 0.170 
GC (n=123) 16(13) 83(67.5) 1.45(0.63-3.33)  21(17.1) 97(78.9) 1.95(0.87-4.38)  
CC (n=40) 3(7.5) 33(82.5) 0.75(0.20-2.72)  4(10) 36(90) 1.1(0.34-3.53)  
Dominant model (GGƗ vs. GC+CC)   1.26(0.56-2.85) 0.565   1.74(0.78-3.84) 0.158 
Recessive model (GG+GCƗ vs. CC)   0.58(0.18-1.84) 0.346   0.69(0.25-1.87) 0.46 
VEGF-A rs3025039*         
CC =190  19(10) 133(70) 1(reference) 0.633 25(13.2) 155(81.6) 1(reference) 0.826 
CT+TT=59 7(11.9) 39(66.1) 1.26(0.25-6.36)  7(11.9) 48(81.4) 0.91(0.41-2)  
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4.6.2 VEGF-A SNPs and prognosis of advanced disease: stage III-IV 
patients. 
   Given the low number of patients classified as ATA high risk (9 subjects, 
4%), this analysis was exclusively performed on stage III-IV patients, 
including tumours with any extra-thyroidal extension and/or more than 4 cm in 
size. Persistent structural disease, recurrent structural disease, and NED were 
considered as clinical endpoints. Only 45 out of 249 patients were included, 
and this represents a limit of this analysis.  
   Results are reported in Table 7. No statistically significant associations were 
found (p>0.05). Nevertheless, a significant trend was observed for the 
association between the AA and CC genotypes of -2578 C>A and -460 T>C 
and NED (p=0.065 for both genotypes). Particularly, RRs of showing NED at 
last follow-up were 0.38 for both genotypes, indicating lower likelihood of 
being disease-free at final follow-up and therefore a negative prognostic 
impact. 
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Table 7. Relationship between VEGF-A polymorphisms and clinical outcome in AJCC/UICC stage III-IV DTC patients. 
 
N:number; AJCC/UICC: American Joint Commettee on Cancer/Union for International Cancer Control; ATA: American 
Thyroid Association. ƗSubgroup considered as reference for the assessment of the relative risk. *Polymorphisms analyzed 
exclusively by means of dominant model because of a Minor Homozygous Genotype frequency≤10%. 
 
 
 
 
 
 
 Persistent structural disease, N(%) Recurrent structural disease, N(%) NED, N(%) 
 Yes No 
Relative 
risk(95%CI) p-value Yes No 
Relative risk 
(95%CI) p-value Yes No 
Relative risk 
(95%CI) p-value 
VEGF-A rs699947             
CC=92 2(2.2) 14(15.2) 1(reference) 0.09 3(3.3) 11(12) 1(reference) 0.809 8(8.7) 8(8.7) 1(reference) 0.177 
CA=113 0(0) 26(23) Not assessable  8(7.1) 18(15.9) 1.43(0.45-4.56)  14(12.4) 12(10.6) 1.07(0.58-1.97)  
AA=44 2(4.5) 8(18.2) 1.6(0.26-9.61)  2(4.5) 6(13.6) 1.16(0.24-5.57)  2 (4.5) 8(18.2) 0.4(0.1-1.51)  
Dominant model (CCƗ 
vs. CA+AA) 
  0.44(0.06-2.88) 0.386   1.37(0.44-4.25) 0.572 
  
0.88(0.48-1.63) 0.711 
Recessive model 
(CC+CAƗ vs. AA) 
  4.2(0.67-26.3) 0.104   0.9(0.24-3.34) 0.885 
  
0.38(0.1-1.36) 0.065 
VEGF-A rs833061             
TT=91 2(2.2) 14(15.4) 1(reference) 0.09 3(3.3) 11(12.1) 1(reference) 0.809 8(8.8) 8(8.8) 1(reference) 0.177 
TC=113 0(0) 26(23) Not assessable  8(7.1) 18(15.9) 1.43(0.45-4.56)  14(12.4) 12(10.6) 1.07(0.58-1.97)  
CC=45 2(4.4) 8(17.8) 1.6(0.26-9.61)  2(4.4) 6(13.3) 1.16(0.24-5.57)  2(4.4) 8(17.8) 0.4(0.1-1.51)  
Dominant model (TTƗ  
vs. TC+CC) 
  0.44(0.06-2.88) 0.386   1.37(0.44-4.25) 0.572 
  
0.88(0.48-1.63) 0.711 
Recessive model 
(TT+TCƗ vs. CC) 
  4.2(0.67-26.3) 0.104   0.9(0.24-3.34) 0.885 
  
0.38(0.1-1.36) 0.065 
VEGF-A rs2010963             
GG (n=86) 2(2.3) 17(19.8) 1(reference) 0.75 2(2.3) 15(17.4) 1(reference) 0.184 9(10.5) 10(11.6) 1(reference) 0.973 
GC (n=123) 2(1.6) 27(22) 0.65(0.1-4.26)  10(8.1) 17(13.8) 3.14(0.78-12.66)  13(10.6) 16(13) 0.94(0.50-1.76)  
CC (n=40) 0(0) 4 (10) Not assessable  1(2.5) 3(7.5) 2.12(0.25-18.04)  2(5) 2(5) 1.05(0.35-3.13)  
Dominant model (GGƗ 
vs. GC+CC) 
  0.57(0.08-3.76) 0.561   3.01(0.75-12.05) 0.077 
  
0.96(0.52-1.75) 0.894 
Recessive model 
(GG+GCƗ vs. CC) 
  Not assessable 0.548   0.91(0.15-5.35) 0.922 
  
1.09(0.39-3.04) 0.872 
VEGF-A rs3025039*             
CC =190  3(1.6) 34(17.9) 1(reference) 0.860 10(5.3) 24(12.6) 1(reference) 0.572 19(10) 18(9.5) 1(reference) 0.238 
CT+TT=59 1(1.7) 14(23.7) 0.82(0.93-7.29)  3(5.1) 11(18.6) 0.72(0.23-2.25)  5(8.5) 10(17) 0.64(0.29-1.41)  
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4.7 Haplotype analysis of VEGF-A SNPs and association with clinical 
outcome in stage I-II and ATA low-intermediate risk patients. 
   Given that 2 VEGF-A SNPs (-2578 C>A and -460 T>C) showed association 
with recurrent structural disease in stage I-II and ATA low-intermediate risk 
patients, we performed haplotype analysis of the 4 included SNPs of the 
VEGF-A gene, and subsequently assessed haplotypes relationship with 
structural recidivisms. This aimed to identify a possible combined prognostic 
effect of VEGF-A SNPs.  
   Analysis of LD in the overall study population revealed a strong association 
between the 3 neighbour loci -2578 C>A (rs699947), -460 T>C (rs833061), 
and +405 G>C (rs2010963), as reported in Table 8. Particularly, the prognostic 
relevant SNPs -2578 C>A and -460 T>C showed complete LD (D’=1 and 
r
2
=0.98). 
 
 
Table 8. Linkage disequilibrium between the 4 VEGF-A SNPs (-2578 C>A, -460 T>C, +405 G>C, 
and +936 C>T)  assessed by means of Lewontin coefficient (D’) and coefficient of correlation of r2. 
 
 
 
SNPs SNPs D’ R2 
-2578 C>A (rs699947) 460 T>C (rs833061) 1,00 0,98 
-2578 C>A (rs699947) +405 G>C (rs2010963) 1,00 0,47 
-2578 C>A (rs699947) +936 C>T (rs3025039) 0,28 0,02 
-460 T>C (rs833061) 
+405 G>C (rs2010963) 0,99 0,46 
-460 T>C (rs833061) 
+936 C>T (rs3025039) 0,28 0,02 
+405 G>C (rs2010963) +936 C>T (rs3025039) 0,17 0,00 
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Three common haplotypes with frequency above 10% were defined by means 
of Haploview program based on population frequencies of the SNPs (Figure 3).  
 
 
 
 
 
 
These include: the -2578C, -460T, +405C (named CTC) haplotype;   the -2578A, -
460C, +405G (named ACG) haplotype; the -2578C, -460T, +405G (named CTG) 
haplotype. Haplotypes frequencies were similar if considering the overall study 
cohort, stage I-II, and ATA low-intermediate risk patients (Table 9.). However, 
estimated frequencies for each haplotype were consistent with those reported 
for other Caucasian populations (Zhai et al. 2008).  
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Comparison of estimated haplotypes frequencies between patients with and 
without recurrent structural disease (results reported in Table 10.) revealed 
significant prognostic effect for ACG and CTG haplotypes in both stage I-II 
(p=0.05 and 0.005, respectively) and ATA low-intermediate risk patients 
(p=0.036 and 0.039, respectively). Particularly, the ACG haplotype confers 
protection (stage I-II: 25% and 40.2% for recurring and non recurring patients, 
respectively, OR=0.22 [95% CI 0.11-0.46];  ATA low-intermediate: 25.9% and 
40.7% for recurring and non recurring patients, respectively, OR=0.51 [95% CI 
0.27-0.97]), whereas the CTG confers risk for structural recurrence (stage I-II: 
34.1% and 16.6% for recurring and non recurring patients, respectively,  
OR=2.6 [95% CI 1.31-5.17]; ATA low-intermediate: 29.6% and 17.8% for 
recurring and non recurring patients, respectively, OR=1.93 [95% CI 1.02-
3.67]). This was consistent with results from the genotype analysis reporting a 
negative prognostic impact for the AA and CC genotypes of -2578 C>A and -
460 T>C. 
 
Table 9. Common VEGF-A haplotypes and frequencies in overall study cohort, AJCC/UICC stage 
I-II, and ATA low-intermediate risk patients. All p-values>0.05. 
 
AJCC/UICC: American Joint Commettee on Cancer/Union for International Cancer Control; 
ATA: American Thyroid Association. 
 
 
Haplotype 
Frequency % 
in overall study cohort 
Frequency % 
in AJCC/UICC stage I-II 
Frequency % 
in ATA low-intermediate 
CTC 40.4 41.6 40.9 
ACG 40.4 39.3 39.4 
CTG 18.9 18.5 19.3 
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Table 10. Common VEGF-A haplotypes and association with recurrent structural disease in stage 
I-II and ATA low-intermediate risk patients. 
 
AJCC/UICC: American Joint Commettee on Cancer/Union for International Cancer Control; 
ATA: American Thyroid Association; OR: Odds ratio; CI: Confidence interval. 
 
4.8 Combined genotype analysis in stage I-II and ATA low-intermediate 
risk patients. 
   Haplotype analysis, using the Haploview software,  relies on estimates of 
frequencies and determines only the likelihood of the haplotipic phase for each 
individual. Thus, this kind of analysis is useful for identifying prognostic 
effects related to SNPs combination, but cannot estimate individual haplotype. 
To overcome this limit, we tried to identify combined genotypes having 
prognostic effect. Basing on results from the genotype (single SNP) and 
haplotype analysis, we decided to assess prognostic impact (namely the 
association with recurrent structural disease) of the combination of the SNPs -
2578 C>A, -460 T>C, and +405 G>C in a recessive model.  
   Results are reported in Table 11. As expected, the ACG homozygous 
genotype (ACG+/+) offered a protective effect against structural recurrence in 
both stage I-II (p=0.018, RR 0.2, 95% CI 0.02-1.42) and ATA low-
intermediate (p=0.035, RR 0.17, 95% 0.02-1.22) risk patients. Importantly, 
ACG+/+ showed p-values and RRs exactly consistent with those demonstrated 
Haplotype 
Frequency % recurrent/non 
recurrent patients AJCC/UICC 
stage I-II 
 
p-value 
 
OR(95% CI) 
Frequency % 
recurrent/non 
recurrent patients ATA 
low-intermediate 
p-value 
 
OR(95% CI) 
CTC 
40.9/42.6 
0.831 
0.93(0.49 
1.77) 
44.4/41 0.239 1.15 (0.65-
2.04) 
ACG 
25/40.2 
0.05 
0.22 (0.11-
0.46) 
25.9/40.7 0.036 0.51 (0.27-
0.97) 
CTG 
34.1/16.6 
0.005 
2.60 (1.31-
5.17) 
29.6/17.8 0.039 1.93 (1.02-
3.67) 
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by analysis of single SNPs (namely the -2578 C>A and -460 T>C) and 
therefore no additional prognostic information was provided by analysis of 
combined genotypes. By contrast, the CTG homozygous genotype (CTG+/+) 
was significantly associated to higher rate of structural recurrence in stage I-II 
(p=0.018, RR=3.55, 95% CI 1.39-9.08), and was slightly deleterious also in 
ATA low-intermediate risk subjects (p=0.079, RR=2.59, 95% 0.97-6.95), 
where the absence of statistical significance was likely due to the low number 
of CTG subjects (9 out of 231). The identification of the CTG+/+ genotype as 
deleterious prognostic marker represented, indeed, an improvement as 
compared with single SNP analysis, where no negative prognostic markers 
were found. Survival analysis, having DFS as primary endpoint, further 
confirmed the prognostic role of ACG+/+ and CTG+/+ genotypes (Figure 4.).  
 
Table 11. Relationship between combined genotypes CTC+/+, ACG+/+, CTG+/+ and recurrent 
structural disease in stage I-II and ATA low-intermediate risk patients. 
 
AJCC/UICC: American Joint Commettee on Cancer/Union for International Cancer Control; 
ATA: American Thyroid Association; RR: Relative risk; CI: Confidence interval. 
 
 
 
Genotype 
AJCC/UICC Stage I-II ATA low-intermediate risk 
p-value RR(95% CI) p-value RR(95% CI) 
CTC+/+ 0.346 0.58(0.18-1.84) 0.464 0.69(0.25-1.87) 
ACG+/+ 0.018 0.2(0.02-1.42) 0.035 0.17(0.02-1.22) 
CTG+/+ 0.018 3.55(1.39-9.08) 0.079 2.59(0.97-6.95) 
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4.9 PPV and NPV of the ACG+/+ and CTG+/+ genotypes for disease 
recurrence in stage I-II and ATA low-intermediate risk DTC patients.  
   We evaluated the accuracy of the ACG+/+ and CTG+/+ genotypes as 
prognostic markers in DTC, by determining PPV and NPV for the development 
of structural recurrences after the achievement of NED following conventional 
therapeutic approach. Analysis was performed in both stage I-II and ATA low-
intermediate risk patients.  
   Results are shown in Table 12. The 2 genotypes showed remarkable NPV in 
both analyzed subgroups. Particularly, NPV of ACG+/+ was 84.4% (95% CI 
78.03-89.57) and 84.3% (95% CI 78.52-89.11) in stage I-II and ATA low-
intermediate risk patients, respectively; NPV of CTG+/+  was 87.9% (95% CI 
82.48-92.21) and 87.2% (95% CI 82.09-91.24) in stage I-II and ATA low-
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intermediate risk patients, respectively. Nevertheless, given that the major 
mission of prognostic stratification of DTC is to identify the subgroup of 
patients who will develop recurrences, our attention was mainly focused on 
PPV. As expected, PPV of ACG+/+ genotype, which has been previously 
associated to low risk of recurring, was null for stage I-II (0%, 95% CI 0-
11.22) and very low for low-intermediate risk (2.7%, 95% CI 0.07-14.16) 
patients. By contrast, the CTG+/+ genotype, which has demonstrated 
association with occurrence of structural recidivism, showed acceptable PPV, 
namely  42.8% (95% CI 9.9-81.59) in stage I-II and 33.3% (95% CI 7.40-
70.07) in ATA low-intermediate risk subjects.  
 
 
Table 12. Assessment of PPV (positive predictive value) and NPV (negative predictive value) for the 
ACG+/+ and CTG+/+ genotypes among stage I-II and ATA low-intermediate risk DTC patients. 
 
 
 
N: Number; CI: Confidence interval; AJCC/UICC: American Joint Commettee on Cancer/Union 
for International Cancer Control; ATA: American Thyroid Association. 
 
4.10 Multivariate analysis in ATA low-intermediate risk patients 
   Given that the ATA classification is the only system with demonstrated 
ability to predict persistent/recurrent disease, which represents the primary 
endpoint of this study, we decided to perform a multivariate analysis in the 
subgroup of ATA low-intermediate risk patients. Particularly, we decided to 
adjust the ACG+/+ genotype, the only demonstrating statistically significant 
association with recurrent structural disease, for two pathological features 
 AJCC/UICC Stage I-II, N=198 
ATA low-intermediate risk, 
N=226 
Genotype PPV% 95%CI NPV% 95%CI PPV% 95%CI NPV% 95%CI 
ACG+/+ 0 
0-
11.22 
84.4 
78.03-
89.57 
2.7 
0.07-
14.16 
84.3 
78.52-
89.11 
CTG+/+ 42.8 
9.9-
81.59 
87.9 
82.48-
92.21 
33.3 
7.40-
70.07 
87.2 
82.09-
91.24 
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representing well-known prognostic factors in the phase of “early” disease: 
tumour size (assessed through the categorical variable microcarcinoma versus 
macrocarcinoma) and multifocality.  
   Results from this analysis are reported in Table 13. All the factors involved 
in the analysis, namely ACG+/+ genotype, tumour size, and multifocality, 
revealed to be independent prognostic factors of recurrent structural disease 
(p=0.048, 0.008, 0.003, respectively). Particularly, the ACG+/+ genotype 
retained its protective prognostic significance after adjustment, showing 
adjusted OR of 0.12 (95% CI 0.01-0.98). 
 
 
Table 13. Model of multivariate analysis with inclusion of ACG+/+ VEGF-A haplotype, tumour size 
(microcarcinoma vs macrocarcinoma) and multifocality in ATA (America Thyroid Association) 
low-intermediate risk patients. 
 
AJCC/UICC: American Joint Commettee on Cancer/Union for International Cancer Control; 
ATA: American Thyroid Association; OR: Odds ratio; CI: Confidence interval. 
ATA low-intermediate risk Univariate analysis Multivariate analysis 
 
Recurrence 
No 
recurrence 
OR (95%CI) p-value 
Adjusted OR 
(95%CI) 
Adjusted p-
value 
VEGF-A genotype       
AC G+/+ 1(2.7) 36(97.3) 
0.15(0.02-
1.13) 
0.035 
0.12(0.01-0.98) 0.048 
Other haplotypes 31(15.7) 167(84.3) 1(reference)    
Tumor size        
   Microcarcinoma 
3(3.4) 84(96.6) 
0.14(0.04-
0.49) 
<0.0001 
0.18(0.05-0.64) 0.008 
   Macrocarcinoma 29(19.6) 19(12.8)     
Multifocality        
    Yes  
11(12.1) 64(70.3) 
3.97(1.68-
9.34) 
0.001 
3.9(1.59-9.57) 0.003 
    No 15(13.3) 76(67.3) 1(reference)    
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5. Discussion 
   Angiogenesis is considered a hallmark of cancer, being more heavily 
involved in neoplastic progression rather than disease development (Hanahan 
et al. 2000). It is therefore conceivable that the efficiency of angiogenic process 
may significantly affect cancer evolution, and therefore clinical outcome. 
Particularly, a less efficient angiogenic process is expected to exert protective 
action against cancer progression, thus determining better prognosis. 
Importantly, cancer-related neo-vessels formation relies on the use of the host 
angiogenic machinery, thus being strictly dependant from those factors 
affecting physiological angiogenesis (Carmeliet et al. 2011; Dvorak 1986).  It 
has been ascertained that efficiency of human angiogenesis, defined as the 
ability to respond to angiogenic stimuli, including those derived from cancer 
cells, mostly depends from individual genetic background, rather than 
environmental factors (Berrahmoune et al. 2007; Pantsulaia et al. 2004). 
Importantly, the impact of genetic variability on angiogenesis is mainly exerted 
through the modulation of gene expression (Rogers et al. 2012). In humans, the 
absence of  tools for quantifying angiogenic response makes not feasible the 
direct identification of those hereditary traits involved in the modulation of 
angiogenesis. Therefore, information about the so-called “angio-genome” is 
still partial in humans and mainly relies on studies about the association of 
previously identified candidate genes with angiogenesis-related diseases, 
including cancer.  
   SNPs are the major source of human genome variability (Frazer et al. 2007). 
Despite being functionally neutral in the majority of cases, they may affect 
gene expression mainly through the elimination or creation of TFBS. 
Importantly, genes with recognized role in the angiogenic process, are usually 
highly polymorphic. These observations make feasible a role for SNPs in 
affecting human angiogenesis (Rogers et al. 2012). Therefore, a wide number 
of association studies assessing the relationship between selected SNPs of 
angiogenic-related genes, namely those with characterized or suspected 
83 
 
functional effects, with phenotype, and therefore prognosis, of different forms 
of cancer have been performed. The majority of these studies were focused on 
the VEGF-A gene, whom product is the leading molecule in the modulation of 
angiogenesis (Nagy et al. 2007), and SNPs located in  the promoter, the 
5’UTR, and the 3’UTR regions, with demonstrated or suspected impact on 
transcriptional and post-transcriptional gene modulation, were the most studied 
(Arcondeguy et al. 2013).  
   Results were highly heterogeneous and, sometimes, controversial (Eng et al. 
2012), with prognostic effect of some SNPs being demonstrated by some 
authors and rebutted by others. Even, opposite prognostic impact was 
sometimes demonstrated, with different risk alleles reported for a single SNP. 
Discrepancies between studies may be only in part explained by means of 
different ethnicity, as controversial results were also reported within the same 
population (Heist et al. 2008; Masago et al. 2009). Thus, other variables should 
be taken into consideration. Firstly, it seemed that VEGF-A SNPs-related 
prognostic effects were highly tumour specific. It is conceivable that each 
cancer represents an independent model with its own molecular and biological 
features, and this may imply different biological and therefore prognostic 
relevance for angiogenesis. However, some studies demonstrated prognostic 
value for VEGF-A SNPs only in specific stages of the same tumour (Lurje et 
al. 2008).  Indeed, role of VEGF-A may be different according to disease stage, 
due to possible modifications in the balance between pro- and anti- angiogenic 
molecules, and particularly to the production of pro-angiogenic factors other 
than VEGF-A, which is typical of advanced tumours (Carmeliet et al. 2011). 
Another relevant variable is the possible interaction between therapeutic 
strategies and VEGF-A genotypes. For example, Guan et al. (Guan et al. 2010) 
found beneficial effect for the C-allele of the VEGF-A -460 T>C in locally 
advanced non small cell lung cancer. Given that the C-allele was associated to 
increased VEGF-A production, and was therefore expected to worsen the 
prognosis, and that a previous report effectively showed deleterious effect for 
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the allele (Masago et al. 2009), authors explained their controversial finding by 
the fact that the majority of patients had been treated with radiotherapy, thus 
suggesting a possible favourable interaction treatment-genotype. Therefore, the 
performance of different therapeutic approaches may at least partially induce 
discrepancies of VEGF-A SNPs prognostic impact between different tumour 
types and, within the same tumour type, between different stages, due to both a 
direct impact on prognosis and to possible interaction with intrinsic features of 
the angiogenic machinery. To date, only few studies involved the VEGFR-2 
gene, which codifies for the major mediator of VEGF-A effects on 
angiogenesis (Ferrara 2009), whereas no studies have tested yet (to the best of 
our knowledge) the possible association of PDGFRs SNPs with cancer 
prognosis (Rogers et al. 2012). Therefore, conclusive data about possible 
prognostic information deriving from SNPs of these genes are still missing.  
   Besides the possible prognostic implications, understanding the actual role of 
angiogenesis in each tumour type is mandatory due to the development and, in 
many cases, approval of anti-angiogenic drugs for the treatment of different 
forms of cancer (Bridges et al. 2011; Welti et al. 2013). Therefore, the 
characterization of the underlying molecular mechanisms, namely the 
identification of the specific role of each angiogenic molecule, and, even more 
importantly, the phase of disease evolution where angiogenesis exerts the 
major influence, would strongly allow the optimization of anti-angiogenic 
treatment strategies.  
   By the clinical sight, DTC can be defined as a “simple” cancer model. 
Independently from disease stage at diagnosis, conventional therapeutic 
approach is almost similar in all patients, being based on surgery with/without 
RAI, followed by TSH suppressive therapy (Haugen et al. 2016). Afterwards, 
no additional treatments are performed until the development of recurrent 
disease, which is considered the endpoint of the majority of prognostic studies 
about DTC. This homogeneity in patients management makes the assessment 
of clinical outcome less dependent from the interference of differential 
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treatment strategies, as compared with other tumours. Thus, DTC represents a 
feasible model allowing a better comprehension of the actual impact and 
underlying mechanisms of angiogenesis on tumour phenotype, and therefore 
prognosis.  
   As a proof of this concept, consistent results showing relevant role of 
angiogenesis in DTC have been reported by the totality of studies focusing this 
issue. Indeed, several studies performed in last 15-20 years have assessed the 
expression of VEGF-A on tumour tissues from DTC, both by protein detection 
through immunoistochemistry and by mRNA detection through RT-PCR. All 
of them demonstrated not only VEGF-A overexpression in tumour tissue, as 
compared with the normal counterpart, but also a clear association with 
aggressive pathological features, including lymph node and distant metastases, 
and worsened clinical outcome, namely higher rates of recurrent disease 
(Bunone et al. 1999; Kilicarslan et al. 2003; Klein et al. 2001; Lennard et al. 
2001; Salajegheh et al. 2013). Importantly, some studies also reported VEGFR-
2 overexpression, but its association with clinical outcome has not been proved  
(Bunone et al. 1999). Although data are still preliminary and far to be 
conclusive, some studies have suggested a possible role for the PDGF-system 
in DTC. In 2006, Chen et al. (Chen et al. 2006) showed that mRNA and protein 
expression of PDGF-AA and PDGFR-α was increased in thyroid carcinoma 
cell lines compared to benign tissues from thyroid nodular hyperplasia. More 
recently, higher expression of PDGFR-α has been demonstrated in PTC 
harbouring lymph node metastases, as compared with those tumours without 
lymph node involvement (Zhang et al. 2012). Furthermore, a recent study by 
Cong et al. (Cong et al. 2015), based on gene expression profiling of DTC 
samples obtained from The Cancer Genome Atlas, demonstrated association of  
PDGFR-α expression and aggressive clinico-pathological features.  
   To date, studies about the relationship between angiogenic SNPs and DTC 
are few and poorly conclusive. Particularly, some authors have assessed the 
possible association with disease susceptibility and pathological features, but 
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no reports have been published about the association with clinical outcome. 
The only study analyzing association between germline VEGF-A SNPs and 
DTC was proposed by Hsiao et al. in 2007 (Hsiao et al. 2007).  This was a 
case-control analysis including SNPs -2578 C>A, +405 G>C, and +936 C>T. 
Results were poorly conclusive, as statistically significant findings were found 
only in men, where the A-allele of -2578 C>A was associated to increased risk 
of developing PTC. Furthermore, an association of the allele with the risk of 
lymph node metastases was also reported. More recently, Salajegheh et al. 
(Salajegheh et al. 2011) performed an association study between 3 VEGF-A 
SNPs (-141 A>C, +405 G>C, and +936 C>T) and pathological features of 
DTC, finding that the C-allele of the SNP -141 was associated to lymph node 
metastases, whereas the G-allele of the SNP +405 and the CC genotype of the 
SNP +936 were more common in advanced stages. Despite interesting, these 
data were not conformant to our analysis because genotyping was performed at 
the somatic level. Importantly, authors found no relationship between VEGF-A 
mRNA expression and SNPs, and this confirms the fact that DTC-related 
angiogenesis is mainly related to host and not to tumour genetic characteristics, 
thus empowering our study approach. To date, no studies have been performed 
about the possible association of VEGFR-2 SNPs and DTC. By contrast, Kim 
et al. (Kim et al. 2012) have recently published a paper about the association of 
PDGFRs SNPs and DTC. Authors performed a case-control study, finding that 
two PDGFR-α SNPs located in the promoter, the -635 G>T and the -1309 
G>A, were associated with the risk of developing PTC. Despite performed  at 
the somatic level, this analysis further empowers the thesis of a possible 
involvement of the PDGF-system in DTC. Given this body of evidence, we 
decided to include in our analysis not only SNPs from the VEGF-system, 
encompassing the two main factors of angiogenesis modulation VEGF-A and 
VEGFR-2 (Ferrara 2009; Nagy et al. 2007), but also from the PDGF-system.   
   As already specified in the Materials and Methods section, SNPs were 
selected basing on previous characterization of the functional impact, on 
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previous data about prognostic impact on cancer and, if available, on preceded 
publications focusing their relationship with DTC. Regarding the VEGF-A 
gene, we included 4 well-characterized SNPs (2578 C>A, -460 T>C, +405 
G>C, and +936 C>T), encompassing all regions involved in the regulation of 
gene expression (namely the promoter, the 5’UTR, and the 3’UTR). All of 
them showed enough evidence of affecting gene expression (functional impact 
of each included VEGF-A SNP has been described in the paragraph 1.4.1 
VEGF-A SNPs and cancer). Furthermore, each included VEGF-A SNP had 
already demonstrated prognostic impact in other tumour types (associations of 
included VEGF-A SNPs with prognosis of other tumour types has been 
reported in the paragraph 1.4.1 VEGF-A SNPs and cancer). Regarding the 
VEGFR-2 gene, data about the prognostic impact of related SNPs on cancer 
are still poor. Given that data about the correlation of VEGFR-2 
overexpression and prognosis of DTC are still lacking, we chose to focus our 
analysis on the 2 nonsynonimous cSNPs, namely 1192 C>T and 1719 T>A, 
located in the extra-cellular domain of the receptor, which are involved in the 
modulation of the binding affinity to VEGF-A. Regarding the PDGF-system, 
data about the functional effects related to the SNPs are still unclear and, as 
already discussed, studies about prognostic impact on cancer are missing. 
Basing on the previously cited studies (Chen et al. 2006; Cong et al. 2015; 
Zhang et al. 2012),  which reported that higher PDGFR-α expression was a 
hallmark of PTC and, also, was associated with aggressive disease features, 
and on the Kim’s study, finding that the  PDGFR-α promoter SNPs -635 G>T 
and the -1309 G>A affected susceptibility to develop PTC (although analysis 
was performed at the somatic and not at the germline level) (Kim et al. 2012), 
we decided to include these 2 SNPs in the analysis.  
   Correlations between genotypes of the selected SNPs and clinical outcomes 
(categorized as persistent structural disease, recurrent structural disease, and 
NED, as specified in the Materials and Methods section) in the overall study 
population showed no statistically significant results. Nevertheless, analysis 
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according to recessive model revealed trends of association between the minor 
homozygous genotypes of the VEGF-A SNPs -2578 C>A and -460 T>C (AA 
and CC, respectively) and 2 prognostic endpoints: persistent structural disease 
and recurrent structural disease. Surprisingly, prognostic effect related to these 
genotypes was opposite basing on the considered clinical endpoint. Despite not 
achieving statistical significance, they conferred protection against structural 
recurrences among DTC patients achieving NED after thyroid ablation, but 
were more frequent, as compared with the other genotypes (common 
homozygous and heterozygous), among patients showing persistence of 
structural disease after treatment.  
   It is important to note that the prognostic endpoints recurrent and persistent 
structural disease defines two different sets of DTC patients. The former is 
typical of patients, representing the vast majority, who can be defined as 
having an “early” disease and easily achieve remission after treatment. The 
latter, indeed, typically involves that low portion of  DTC patients having 
“advanced” disease, particularly those with metastatic spread (Tuttle et al. 
2010b; Vaisman et al. 2012). Our study population was consistent with these 
concepts, as the presence of distant metastasis at diagnosis represented the 
strongest clinical predictor of persisting structural disease, but was not 
associated to structural recurrences. Importantly, analysis of genotypes 
association with clinico-pathological factors revealed  that the minor 
homozygous genotypes of VEGF-A -2578 C>A and -460 T>C were strongly 
associated with the presence of distant metastases at diagnosis. Despite being 
based on few cases of metastatic patients (6 subjects), this association 
complicates data interpretation, as the proportion of risk of persistent structural 
disease that is attributable to the highlighted genotypes versus that attributable 
to the presence of distant metastases is difficult to be determined.  
   We thought that more consistent and exhaustive results about prognostic 
impact of VEGF-A SNPs could be derived from the separate assessment of the 
2 described clinical scenarios, namely “early” and “advanced” DTC. Indeed, 
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previous studies of other tumour types have already showed different 
prognostic significance of VEGF-A SNPs according to disease stage (Lurje et 
al. 2008). This could be related both to the use of different treatment strategies, 
which is not the case of DTC where first-line treatment is almost similar 
independently from initial staging, and also, more interestingly, to intrinsic 
modifications of the angiogenic machinery, namely of the balance between 
angiogenic regulating factors, that may occur through different phases of the 
pathological process. Therefore, we performed a stratified analysis trying to 
discriminate between “early” and “advanced” DTC patients. Given that a clear 
distinction between “early” and  “advanced” disease in DTC has not been 
codified yet, we applied the 2 mostly used stratification systems, namely the 
AJCC/UICC and the ATA (Momesso et al. 2014). Particularly, we considered 
as “early” disease 2 DTC subgroups: AJCC/UICC stage I-II subjects, involving 
intra-thyroidal tumours equal or less than 4 cm in size, and ATA low-
intermediate risk patients, including patients without gross extra-thyroidal 
extension (pT4a-b) and without metastatic disease. We found  that both AA 
and CC genotypes of VEGF-A -2578 C>A and -460 T>C were associated with 
significantly lower rate of structural recurrence, and therefore exerted 
protective action against the development of structural recidivisms in both 
subgroups. These findings were further confirmed by analysis of DFS, which 
was significantly higher among patients with the highlighted genotypes, as 
compared with others.  
   Given the extremely low number of subjects classified as ATA high risk, 
which did not allow to perform any statistical analysis, assessment of 
“advanced” disease was only based on AJCC/UICC stage III-IV patients,  
including tumours with any extra-thyroidal extension and/or more than 4 cm in 
size. Analysis showed no statistically significant prognostic impact for the AA 
and CC genotypes of VEGF-A -2578 C>A and -460 T>C. Nevertheless, a 
trend was observed with the likelihood of being NED at last follow-up, which 
is a critical endpoint for patients presenting advanced stages at diagnosis. 
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Particularly, the presence of the highlighted genotypes was associated to lower 
risk of being disease-free at last follow-up, thus suggesting a possible 
deleterious prognostic impact. However, conclusive information about 
“advanced” disease is hampered by the low number of subjects, as our study 
cohort mainly included patients with early stages. A higher number of patients 
with “advanced” DTC, particularly those being metastatic at diagnosis, should 
be analyzed for a more careful evaluation of VEGF-A -2578 C>A and -460 
T>C prognostic impact.  
   Given that statistically significant impact on prognosis was demonstrated  for 
2 VEGF-A SNPs only in stage I-II and ATA low-intermediate risk patients, we 
performed more in depth analyses of VEGF-A related SNPs in these specific 
subgroups of patients. In order to verify possible empowerment of prognostic 
information related to SNPs combination and to obtain more exhaustive 
information about the underlying biology, we performed haplotype analysis 
and assessed haplotypes association with the rate of recurrent structural 
disease. The Haploview software, providing estimates of haplotype 
frequencies, identified 3 common haplotypes involving the SNPs -2578 C>A, -
460 T>C, and +405 G>C, namely CTC, ACG, and CTG. Of them, ACG and 
CTG showed association with prognosis in both stage I-II and ATA low-
intermediate risk patients. As expected from genotype analysis, ACG conferred 
protection against structural disease recurrence, whereas CTG was associated 
to higher risk of recurring.  
   Given that the SNP +405 G>C provides its common G-allele to both the 
protective and deleterious haplotype, a relevant biological role determining an 
actual prognostic impact for this SNP has to be excluded. Conclusive 
information about the actual biological relevance, and therefore prognostic 
impact, for  SNPs -2578 C>A and  -460 T>C, is not possible by means of this 
kind of study, which is based on a SNP-candidate approach. Particularly, gene-
throughout  association studies are needed to exclude that other SNPs or 
genetic markers, in LD with those reported in the present analysis, may be 
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associated with prognosis, and in vitro and in vivo studies are required to 
confirm differential biological effects for polymorphic variants of the 
highlighted SNPs. Basing on our results, we can only perform some biological 
speculations. We have already reported available data about impact of analyzed 
SNPs on VEGF-A function (see paragraph 1.4.1 VEGF-A SNPs and cancer). 
Consistently with the protective effect shown in our analysis, the AA genotype 
of -2578 C>A has been associated with decreased serum levels of VEGF-A, 
and therefore with reduced gene expression (Shahbazi et al. 2002). By contrast, 
a lowered VEGF-A production was reported for the common T-allele of -460 
T>C (Hansen et al. 2010b), which was part of the deleterious haplotype, and 
this was not conformant to our results. Therefore, among the 2 prognostic 
relevant SNPs detected in our study, which are in complete LD, the -2578 C>A 
is that with higher likelihood to play an actual biological role in DTC-related 
angiogenesis and to affect prognosis. Importantly,  elimination/creation of 
TFBS related to this SNP has been carefully described (Metzger et al. 2015), 
thus allowing to discuss about possible biological differences between 
polymorphic variants that could explain the role in DTC. As previously 
reported, the AA genotype is associated to the loss of any binding site for the 
dimer HIF1α/β, which represents the main mediator of hypoxia-inducted 
VEGF-A production (Buroker et al. 2013). By the biological sight, this 
produces a dramatic change as VEGF-A expression, being the main regulator 
of  the angiogenic process, becomes independent from HIF1-mediated hypoxia. 
Notably, HIF1-α overexpression has been associated to molecular and 
morphological changes leading to disease progression (such as the epithelial-
mesenchymal transition) and to aggressive pathological features (including 
advanced stage and lymph node metastases) in DTC, and this suggests a 
relevant role for  HIF1-mediated hypoxia in disease progression of such 
tumour type (Wang et al. 2014; Yang et al. 2015). This is consistent with the 
protective role demonstrated for the AA genotype, where VEGF-A expression, 
and therefore angiogenesis, related to HIF1-mediated hypoxia is hampered by 
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the absence of binding sites within the promoter. Furthermore, the C-allele is 
associated to the presence of a TFBS specific for E2F1, which is a key 
regulator of cell cycle progression mediating proliferative stimulation from 
almost all growth factors (Ertosun et al. 2016).  Importantly, the previously 
mentioned study by Cong et al. (Cong et al. 2015) reported overexpression of 
this transcription factor in PTC. Therefore, the presence of the C-allele 
determines the exposition of the binding site for E2F1, which may in turn 
amplify VEGF-A induction following proliferative stimuli, including those 
generated from cancer cells. These observations, despite preliminary and 
speculative, may provide some rationale for the prognostic significance of 
SNP -2578 C>A emerged by our analysis.  
   Another hot point of our study is the differential prognostic significance of 
the identified genetic markers in patients with advanced disease stage, where 
an absent or, even, pejorative prognostic impact has been reported (although 
results from this set of patients has not been considered conclusive). The main 
hypothesis explaining this issue is that in advanced disease, especially in 
metastatic patients, up-regulation of pro-angiogenic molecules other than 
VEGF-A has been demonstrated, involving fibroblast growth factors, ephrins, 
angiopoietins, and interleukins (Bergers et al. 2008). This cancels the leading 
role of VEGF-A in the modulation of angiogenesis, and may therefore explain 
the loss of prognostic significance of those factors affecting its function, 
including genetic variability related to SNPs. Considering (even if it remains 
just a speculation) the -2578 C>A  as the biologically relevant marker, another 
possible hypothesis may derive from the fact that the A-allele is in LD with a 
18-bp  insertion at position -2549, which harbours at least twelve additional 
TFBS (Brogan et al. 1999; Schneider et al. 2009), and is suspected to enhance 
VEGF-A expression (Supic et al. 2012). It is therefore conceivable that 
modifications of  gene expression occurring in advanced disease may lead to 
the production of a different set of  transcription factors, which may enhance 
VEGF-A expression through the binding to this A-allele related insertion. This 
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may explain the possible deleterious impact of the AA genotype of -2578 C>A  
in advanced DTC.  
   Besides the biological speculations, primary aim of the study was to test the 
selected set of angiogenic SNPs as feasible prognostic markers in DTC, and to 
verify if they can improve current prognostic approach. Main aim of prognostic 
stratification of DTC is to identify that low, but not negligible, portion of 
patients (about 25-30%), who will experience persistent/recurrent disease 
(Castagna et al. 2011; Pitoia et al. 2013; Tuttle et al. 2010b; Vaisman et al. 
2012). Although dedicated categorical classification systems, mainly based on 
clinico-pathological factors, have been recently proposed by the major societies 
dealing with thyroid diseases (Pacini et al. 2006; Pitoia et al. 2013; Pitoia et al. 
2009), PPV for the identification of persisting/recurring patients is still far to 
be optimal (Castagna et al. 2011). Therefore, the ATA has recently introduced 
the “continuum of risk” model, which is an individualized non-categorical 
approach for persistence/recurrence risk estimate including a wider range of 
variables (Haugen et al. 2016). Despite the deep characterization of molecular 
alterations related to DTC, and particularly to PTC (Xing 2013), molecular 
prognostication has only a marginal role in prognostic definition. Indeed, the 
most powerful and best characterized marker, the oncogene BRAFV600E, 
showed poor specificity, and therefore limited PPV, for the prediction of 
persistence/recurrence. Thus, mutated BRAF does not represent a significant 
addition to current prognostic systems and its determination is not routinely 
recommended from the latest 2015 ATA guidelines (Haugen et al. 2016). 
Given this body of evidence, searching for novel molecular prognosticators 
with high specificity and PPV for persistent/recurrent disease is the major 
objective of this research field. Furthermore, molecular prognostication of 
DTC is exclusively based on tissue markers, but accessibility to tumour 
samples is not always feasible. Therefore, providing non-tissutal prognostic 
markers, easily available independently from tissue retrieval, would represent a 
relevant advantage.  
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   Given that Haploview program just calculates the likelihood of the haplotipic 
phase of each individual for allowing inferential analyses, it cannot provide 
molecular markers useful for the characterization of individual risk in clinical 
practice. Therefore, basing on information obtained by single SNP and 
haplotype analysis, we constructed “risk” genotypes by combining VEGF-A 
SNPs -2578 C>A, -460 T>C, and +405 G>C (which were in LD) according to 
a recessive model (given that minor homozygous variants of 2 of these SNPs 
had revealed significant prognostic value), and assessed their prognostic impact 
on the occurrence of recurrent structural disease in stage I-II and ATA low-
intermediate risk DTC patients. As expected, ACG+/+ genotype conferred 
protection against structural recurrence in both subgroups, whereas the 
CTG+/+ conferred significantly higher risk of structural recurrence in stage I-II 
and was deleterious also in ATA low-intermediate risk subjects, where we 
attributed the lack of statistical significance to the low number of subjects 
harbouring the genotype. To further reinforce these data, we proposed a model 
of multivariate regression analysis focusing on the subgroup of ATA low-
intermediate risk patients. Indeed, ATA classification is specifically based on  
prediction of disease recurrence, which represents the endpoint of our study. 
Given that we have found prognostic role and speculated about biological 
impact of identified genetic markers in DTC patients with “early” disease, we 
decided to adjust prognostic impact of the genotype ACG+/+, the only 
achieving statistical significance, for the 2 main prognostic features of “early” 
DTC, namely tumour size and multifocality (Ito et al. 2012; Mazzaferri 2007; 
Roti et al. 2008). Notably, the marker retained its protective effect after 
adjustment, and this partially attests the independent prognostic role of VEGF-
A genetic variability. Indeed, this result is limited by the fact that restricting 
analysis only to patients with low risk according to ATA was not feasible given 
the too low number of patients harbouring the risk genotype.  
   In order to assess prognostic accuracy and compare these markers to the 
current set of variables available for DTC prognostication, we calculated PPV 
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and NPV for recurrent structural disease. As expected from the association 
with reduced risk of recurrence, ACG+/+ genotype showed considerable NPV 
but extremely poor PPV. Therefore, this marker is not useful for selecting those 
patients with significant risk of recurrence. However, it may be included within 
the set of variables considered for quantifying the risk estimate of recurrence 
according to the “continuum of risk” model. More relevantly, CTG+/+ 
genotype displayed not only considerable NPV, but also acceptable PPV, 
which was 42.8% and 33.3% in stage I-II and ATA low-intermediate risk 
subjects, respectively. According to our analysis (which needs to be confirmed 
and possibly refined by further studies) and to the best of our knowledge, 
CTG+/+ genotype represents the most powerful molecular marker allowing the 
identification of those patients affected with “early” DTC (stage I-II and ATA 
low-intermediate risk are considered under this definition) who will develop 
structural recurrence. Indeed,  the BRAF mutation, currently considered as the 
best molecular prognosticator in this field, showed PPV of only 25% in the 
largest meta-analysis available to date (Tufano et al. 2012). Despite being the 
highest reported for a molecular marker (according to our knowledge), PPV of 
CTG+/+ genotype for disease recurrence is acceptable but still limited. 
Therefore, future studies about its association with BRAFV600E as well as other 
molecular features having prognostic relevance (i.e. mutations of p53 and 
TERT promoter) are mandatory for verifying possible correlation and 
prognostic empowerment from markers combination.  
   Importantly, clinical management of many subgroups of patients included in 
the heterogeneous group of “early” DTC presents several controversies 
(McLeod et al. 2013). Particularly, the absence of randomized controlled trials 
makes challenging several therapeutic aspects, including the extent of surgery 
(Barney et al. 2011; Bilimoria et al. 2007; Haigh et al. 2005; Mendelsohn et al. 
2010), prophylactic central node dissection (Perrino et al. 2009; Popadich et al. 
2011; Shan et al. 2012; Zetoune et al. 2010), and RAI-treatment (Sacks et al. 
2010; Sawka et al. 2008). Therefore, an improvement in the capability of 
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predicting disease recurrence represents a relevant breakthrough, as it may 
significantly optimize clinical decision-making. Furthermore, the selection of a 
subgroup of patients with higher risk of disease recurrence by means of genetic 
features affecting VEGF-A activity, may provide the rationale for testing new 
therapeutic strategies based on the introduction of treatments specifically 
targeting the VEGF-A, such as the neutralizing antibody bevacizumab. To 
date, anti-angiogenic treatment of DTC exclusively relies on the use of 
tyrosine-kinase inhibitors, which are multimodal drugs exerting anticancer 
activity by means of both anti-proliferative and anti-angiogenic function 
(Smith et al. 2004). Up to now, these compounds, being sorafenib and 
lenvatinib those approved by the US Food and Drug Administration, have been 
exclusively used in the uncommon setting of RAI-refractory macro-metastatic 
patients showing morphological disease progression  (Marotta et al. 2012; 
Marotta et al. 2015). Therefore, they are not part of the conventional 
therapeutic approach. Nevertheless, the use of VEGF-A blockage, mainly by 
means of bevacizumab, has been tested and, in some case, introduced into 
clinical practice in the adjuvant setting of several tumour models (Jain et al. 
2006). The validation of CTG+/+ genotype as predictor of significant risk of 
recurrence among DTC patients with an initially “early” disease may justify 
the planning of randomized clinical trial assessing the impact of bevacizumab, 
administered as adjuvant treatment after thyroidectomy, on the rate of disease 
recurrence.  
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6. Conclusions 
   This is the first study assessing possible prognostic impact of a set of 
germline SNPs of angiogenesis-related genes, namely VEGF-A, VEGFR-2, 
and PDGFR-α, on clinical outcome of a large cohort of DTC patients.  
   We found that analysis of germline VEGF-A SNPs may provide stable and 
easily accessible prognostic markers in the setting of “early” DTC, including 
patients with AJCC/UICC stage I-II and ATA low-intermediate risk of disease 
recurrence. Particularly, single-SNP, haplotypes, and combined-SNPs analyses, 
led to the identification of 2 molecular markers with possible role in prognostic 
stratification of DTC. These include the ACG homozygous genotype, termed 
ACG+/+, and the CTG homozygous genotype, termed CTG+/+, of the SNPs -
2578 C>A (rs699947), -460 T>C (rs833061), and +405 G>C (rs2010963). 
Both these markers showed significant association with the rate of structural 
recurrences, with the ACG+/+ being the protective genotype and the CTG+/+ 
conferring higher risk of recidivism. Of them, the CTG+/+ may more 
relevantly impact on clinical practice, as it showed the highest PPV for disease 
recurrence reported to date for any molecular prognosticator, thus improving 
the capability to discriminate “early” DTC patients who will develop 
recurrences after thyroid ablation, which represents the main aim of prognostic 
definition of DTC. The validation of this marker and its combination with other 
genetic features may facilitate decision-making of these patients,  which is still 
challenging regarding several therapeutic aspects. Importantly, the relevance of 
VEGF-A genetic variability, affecting gene function, in the early phase of the 
disease may provide rationale for introducing VEGF-A targeted therapy in this 
setting.  
   Data about prognostic impact of VEGF-A SNPs in “advanced” disease were 
partial and not conclusive, given that study cohort mainly included patients 
with “early” disease. Nevertheless, single-SNP analysis suggested absent or, 
even, deleterious prognostic value for SNPs -2578 C>A and -460 T>C, which 
were, indeed, protective in “early” DTC. It is conceivable that this discrepancy 
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was related to the loss of VEGF-A dependency of the cancer-related 
angiogenic process and/or to modified production of transcription factors 
affecting VEGF-A expression, which may occur in advanced tumours. 
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This group of papers focus the possible biological difference between 
clonal and non-clonal RET rearrangements, trying to make light on the 
related clinical implications. Our study dealing with this aspect 
culminated in a review paper published on the “European Journal of 
Endocrinology”, where current role of RET/PTC in thyroid diseases, 
both malignant and benign, is described.  
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These papers are focused on biology and prognostic implications of the 
BRAF mutation in PTC. The first 2 articles aimed to determine, by 
means of the quantitative technique named pyrosequencing (whom 
accuracy was verified by our group even in cytology samples from DTC 
patients with concurrent Hashimoto’s thyroiditis), if the BRAF mutation 
occurs clonally, as expected from its recognized pathogenetic and 
prognostic role, or may also be a subclonal event. This aspect is still 
discussed in literature. We demonstrated clonality only in a subgroup of 
patients. We also attested significance of this biological finding 
demonstrating that the percentage of BRAF-mutated alleles correlates 
with clinical outcome. The fourth paper, indeed, analyzed the interaction 
between BRAFV600E and concurrent Hashimoto’s thyroiditis in affecting 
clinical outcome of PTC, given that they exert significant but opposite 
prognostic influence. 
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This is a series of clinical papers dealing with current role of anti-
angiogenic treatment in endocrine tumours, and specifically in DTC. 
This is consistent with the submitted thesis, whom objective is also to 
provide new information about the biological role and the underlying 
mechanisms of angiogenesis in DTC. Particularly, we provided 
innovative insights about treatment strategies, based on the use of 
tyrosine-kinase inhibitors, to be applied in the setting of DTC refractory 
to radiometabolic treatment. Our research culminated in a review paper 
published on “Critical Review in Oncology/Hematology”, which is the 
official journal of the “European Society of Oncology”.  
